2025
Sustainability Report

亿帆医药股份有限公司
YIFAN PHARMACEUTICAL CO.,LTD.

Striving To Eliminate Human Diseases



Table of Contents

CATALOGUE

Report Description

Report Cycle

Annual Report

Reporting Period

January 1, 2025 to December 31, 2025

Report Introduction

This is the second sustainability report (hereinafter referred to as “this report”) released by Yifan Pharmaceutical Co., Ltd. (hereinafter referred to as “Yifan Pharmaceutical”, “the Company”, or “we”). It aims to present to stakeholders our sustainability philosophy, management approaches, progress, and achievements during 2025.



Reliability Assurance

The Board of Directors of the Company reviewed and approved this report on April 22, 2026. The Company guarantees that there are no false records or misleading statements in this report.

Basis of Preparation

- *GRI Sustainability Reporting Standards* issued by the Global Reporting Initiative (GRI);
- International requirements such as ISO 26000:2010 *Guidance on Social Responsibility* issued by the International Organization for Standardization;
- National standard GB/T 36001-2015 *Guidance on Social Responsibility Reporting*;
- *Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation)* and *Self-Regulatory Guidelines No. 3 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report* issued by the Shenzhen Stock Exchange;
- *Corporate Sustainability Disclosure Standards—Basic Standards (Trial)* issued by the Ministry of Finance of the People’s Republic of China;
- Referring to and responding to the United Nations Sustainable Development Goals (SDGs).

Report Scope

To ensure the continuity of information, certain content has been retrospectively reviewed and expanded upon. Any information falling outside the reporting period will be clarified where relevant. Unless explicitly stated otherwise in this report, the information disclosed herein encompasses Yifan Pharmaceutical Co., Ltd. and its subsidiaries, aligning with the scope of the consolidated financial statements in the 2025 Annual Report of Yifan Pharmaceutical (SZ: 002019). For details regarding the data coverage of this report, please refer to the "Appendix (I) Key Performance Table" section.

Data Description

The data is sourced from the Company's internal documents, reports, and relevant statistical data. Unless otherwise specified, all amounts in this report are denominated in Renminbi (RMB).

Data Statement

The company guarantees that there are no false records, misleading statements, or material omissions in the content of this report, and assumes corresponding responsibility for the authenticity, accuracy, and completeness of its content.

Release Format

To reduce resource waste and environmental pollution, this report is published in electronic format and is available on the Shenzhen Stock Exchange website (https://www.szse.cn/index/) and CNINFO website (www.cninfo.com.cn). This report is published in both Chinese and English. In the event of any discrepancy between the two versions, the Chinese version shall prevail.

Prepared by

Yifan Pharmaceutical Co., Ltd.

Contact Information

Address: Yifan Pharmaceutical, Intersection of Yingjiangsi Road and Fanhua Avenue, Taohua Town, Feixi County, Hefei City, Anhui Province

Postal code: 231200
Telephone: 0551-62672019
Fax: 0551-66100530

Business inquiry hotline: 400-180-2019Overseas
business inquiries: overseas@yifanyy.com
Official website: www.yifanyy.com

Chairman's Address

Looking back, 2025 was a year in which Yifan Pharmaceutical forged ahead through challenges and transformation. Facing the "harsh" reality of industry consolidation, stricter regulation, and rising barriers to globalization, we set our course with "scientific planning" and reinforced our long-term commitment to Environmental, Social, and Governance (ESG) responsibilities with steady steps. Over the past year, we not only "strove to grow" in our business operations but also delved deeply into our responsibilities, embedding the philosophy of sustainable development into the company's internal driving force. As we release our second sustainability report, we are pleased to share with you our practices and reflections in the field of sustainable development over the past year.

With a healing heart, we expand the boundaries of life through innovation. R&D innovation is the vital lifeline of Yifan Pharmaceutical's sustainable growth, and our most profound commitment to patients, upheld consistently over time. In 2025, the supplemental application for the 24-hour dosing regimen of Ryzneuta® was approved in China and the product was included in multiple authoritative clinical guidelines in China and abroad, while global shipments increased by over 80% year on year, benefiting patients worldwide. The Class 1 innovative drug N-3C01 Injection was approved to enter clinical trials for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer, and the Phase Ib clinical trial of Duanjin Jiedu Capsules achieved its expected objectives. Compound Huangdai Tablets achieved landmark results in the treatment of ovarian cancer, and Compound Yinhua Jiedu Granules advanced toward the pediatric influenza indication... Behind every medicine lie the hopes of countless families and our steadfast response to the mission of "striving to eliminate human diseases".

With unstoppable momentum, we connect global health through our expanding presence. From China to Europe, from Southeast Asia to the Americas, Yifan's expertise and solutions are reaching ever farther. Ryzneuta® was approved for marketing in Thailand and Malaysia, Amikacin Sulfate Injection was successfully shipped to Italy, Oxytocin Injection was launched in Tajikistan, and Diazoxide Oral Suspension was urgently exported to Brazil... our global market footprint continued to expand. Maqin Xiaoke Granules, Ginkgo Leaf Pills, and several other products were exported for the first time or exported again, making the overseas expansion of traditional Chinese patent medicines a normalized endeavor. The first domestically manufactured product, Norepinephrine Bitartrate Concentrated Solution for Injection, passed the PIC/S inspection by Singapore's HSA. Yinikang® domestic repackaging passed the Korean MAH on-site audit and obtained a GMP compliance notice. The Company also secured promotion rights for Nilotinib Capsules in Colombia and Central America, Abiraterone Tablets in Mexico and Central America, Dydrogesterone Tablets in the Philippines, and Dapagliflozin and Metformin Tablets in the Latin American market. The cornerstone of our global supply chain is being built brick by brick by the Yifan team.

Embracing far-sighted wisdom, we foster in-depth collaboration for mutual prosperity. We firmly believe that a company's sustainable development originates in the creativity of its people and is realized through the collaborative strength of its ecosystem. Internally, we let those closest to the front line make decisions, driving organizational transformation to greater depth and unleashing agility and creativity at the business front end; we continue to improve our talent development system and career pathways, and effectively enhance employees' sense of gain, happiness, and belonging. Externally, we build an open ecosystem of mutual benefit and shared prosperity through measures such as green supplier screening, deeper localized procurement, and stronger integrity management of suppliers, striving to establish deep collaboration and a virtuous cycle of mutual achievement with global R&D institutions, business partners, and medical institutions. By connecting through openness, resonating through connection, and prospering through resonance, we are weaving a warm and resilient network to safeguard health.

By upholding integrity and sound rules, we cultivate fertile ground for development through standardized governance. We know that only by moving steadily can we go far. To this end, we continue to optimize compliance governance, improve our internal control system, and strictly enforce anti-corruption and anti-commercial bribery policies, using compliant operations to safeguard the bottom line for development; in investor communications, we remain transparent, timely, and accurate, disclosing information on corporate operations and sustainable development in accordance with regulations and candidly responding to stakeholder concerns; and we integrate green and low-carbon principles throughout production, procurement, and the entire supply chain, continuously optimizing manufacturing processes, promoting equipment upgrades and energy-efficiency improvements, advancing waste treatment and pollution prevention, and encouraging all employees to practice conservation. Through practical action, we respond to the national "dual carbon" goals and strive to build an environmentally friendly enterprise.

The pharmaceutical and healthcare industry is a long-distance race measured by life itself. On this journey, which carries heavy expectations, sustainable development is the very foundation of survival for pharmaceutical companies and a choice we actively embrace. Over the next three years, Yifan Pharmaceutical will stay anchored to the goal of becoming "a benchmark Chinese pharmaceutical company with a global presence," keeping pace with the times and resonating with national priorities, integrating responsibility into strategy and goodwill into action, and working hand in hand with all parties to press forward tirelessly on the path of healing disease.

May every step be firm and resolute, and may every journey be warm and promising.

Chairman:

Cheng Xianfeng

About Us

Company profile

Yifan Pharmaceutical is an innovative R&D-driven pharmaceutical enterprise. Established on November 10, 2000, with its registered office in Hangzhou, Zhejiang Province, the Company was listed on the Shenzhen Stock Exchange in 2004 under the stock code SZ: 002019. Through continuous R&D breakthroughs and high-quality pharmaceutical products and services, Yifan Pharmaceutical brings health and hope to patients around the globe, striving to grow into a professional and dynamic new force in the global pharmaceutical and healthcare industry.

Yifan Pharmaceutical upholds the cultural values of “pragmatism, innovation, integrity, and diligence” and takes “striving to eliminate diseases for humans” as its mission. The Company is committed to becoming a new contributor of expertise in the global pharmaceutical and health industry. Yifan Pharmaceutical adheres to a development plan of “innovation and internationalization” and integrates the ESG concept of “safe, controllable, and sustainable development” into its actions, promoting harmonious coexistence between the enterprise, society, and the environment.

Business layout

The Company has established a global production and R&D system, as well as a commercial network, centered around four key business areas: biologics, small molecules, synthetic biologics, and specialty Traditional Chinese Medicine. Through a diversified product portfolio and strategies centered on innovation and internationalization, the Company has secured a significant position in the pharmaceutical and healthcare industry.

Biologics

We focus on the R&D and industrialization of biologics, concentrating on oncology, inflammatory diseases, and metabolic disorders. Our strategic priority is to develop globally competitive innovative drugs, improved biologics, and biosimilars. Driven by the dual engines of “independent R&D + international collaboration”, we have built a product matrix anchored by our “DiKine™ dual-molecule platform” and “LaMbs long-acting dual-antibody platform”.

Small molecule drugs

Based on “special APIs + high-end excipients”, we focus on a differentiated portfolio of chemical drugs characterized by “small scale, cutting-edge technology, and unique features”. We possess a high-end chemical drug R&D and manufacturing platform and a quality management system that meets international standards. Our product portfolio includes Capecitabine Tablets (Xeloda®), Laevolac® Lactulose Oral Solution, Emedastine Difumarate Sustained-Release Capsules, BDDE-Crosslinked Sodium Hyaluronate Injection (Euflexxa®), and Oxytocin Nasal Spray, among others, comprehensively meeting diverse market demands.

TCM patent formulations

TCM patent formulation sector represents the Company’s traditional area of strength, driven by the competitiveness of “proprietary products + inclusion in the National Reimbursement Drug List (NRDL)”. We hold 108 TCM drug approval numbers, including 14 proprietary TCM products covered by the NRDL, such as Baixuekang (Compound Huangdai Tablets), Xiao’er Qingqiao Granules, Dehumidifying and Anti-Itch Ointment, Piminxiao Capsules, Fuyinkang Lotion, and Fufang Yinhua Jiedu Granules. Additionally, we have been awarded 2 National Awards for Scientific and Technological Progress, 1 national secondary protected Traditional Chinese Medicine variety, 1 entry in the WHO Model List of Essential Medicines, and 5 products registered overseas. This positions our company as one of the domestic pharmaceutical enterprises with a substantial number of proprietary products, particularly those with proprietary NRDL or National Essential Medicines List status.

Synthetic biologics

The Synthetic Biologics Business Division focuses on two primary areas: “nutrition” and “personal care”. We are systematically advancing the development of an integrated “R&D–Production–Commercialization” value chain. While consolidating our market position for existing products to ensure baseline performance, we are actively promoting the construction and commissioning of new projectsand pursuing both domestic and international certifications, thereby forging a new trajectory for growth.

Major events in 2025

Business performance

- **Overall operations:** In 2025, the Company achieved total operating revenue of RMB 5.133 billion. Net profit attributable to shareholders of the listed company of RMB **402 million**, with a **4.16%** year-on-year increase , maintaining overall operational stability.
- **Core pharmaceutical business:** Pharmaceutical revenue reached RMB 4.358 billion, up 2.30% year-on-year. Revenue from proprietary pharmaceutical products (including imports) amounted to RMB 3.837 billion, a 4.71% year-on-year increase, of which domestic revenue from proprietary pharmaceutical products (including imports) reached RMB 3.304 billion, surging by 4.86% year-on-year, serving as the cornerstone of business performance.
- **Commercialization of innovative drugs:** Initial results have begun to emerge from the global commercialization of Ryzneuta®, with total external shipments in China and overseas exceeding 500,000 units, up more than 80% year on year, contributing to the growth of revenue from the Company's proprietary products.

R&D progress

- **Biologics R&D:** We completed F-652 process optimization and received approval for a Phase II clinical trial in China for the indication of graft-versus-host disease. We also obtained clinical trial approval for the biologic drug N-3C01 Injection for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer, as well as clinical trial approvals for Insulin Glargine and Human Growth Hormone Injection.
- **R&D of TCM:** We concluded the Duanjin Anti-Addiction Capsules Phase Ib clinical trial for relapse prevention in the treatment of opioid addiction, completed the Phase III clinical trials for Fufang Yinhua Jiedu Granules in treating pediatric influenza and submitted the product for regulatory approval.
- **New synthetic biologics:** The vitamin B6 production line completed installation and entered the testing phase. The HMO product 2'-FL received FDA GRAS certification in the U.S. and domestic approval in China. The HMO product 6'-SLreceived FDA SELF-GRAS certification in the U.S.
- **Domestic and international registration, filings and approvals:** The Company has completed regulatory submissions to China's Center for Drug Evaluation (CDE) for Revefenacin Inhalation Solution and Vinorelbine Tartrate Injection, and obtained Chinese drug registration certificates for six products, including Eptazocine Hydrobromide. Oxytocin Injection was approved in Tajikistan. Sugammadex Sodium Injection was approved in the United States. Norepinephrine Bitartrate Injection was filed in Singapore.

Global commercial operations

- **Business system integration:** We established the Global Business Division to integrate the domestic pharmaceutical sales system with the International Business Division. The Global BD Center was set up to actively promote the "bringing in" and "going global" of products.
- **Global approvals and collaborations for Ryzneuta®:** The Company has obtained new market approvals in Thailand and Malaysia, bringing the total number of countries where it has received marketing authorization to 36. It has also established commercial partnerships with 14 markets, including Croatia and Australia, with overseas shipments exceeding 500,000 units, representing a year-on-year growth of over 80%.



NAMA PRODUK	BAHAN AKTIF	PENGILANG	NO. PENDAFTARAN
RYZNEUTA 20mg (efbemalenograstim alfa) Solution for injection in Prefilled Syringe	Efbemalenograstim alfa 20mg/ml	Evive Biopharmaceutical (Beijing) Ltd. (China)	MAL25116003ACZ

Perkara tersebut di atas adalah dirujuk.

Ryzneuta® Approved for Launch in Thailand and Malaysia

- **Product in-licensing:** The Company has obtained exclusive marketing rights in mainland China for Stivarga® and Nexavar® from Bayer, as well as for the Tecfidera™ from Biogen, and substantially reached agreements on the manufacturing and commercialization collaboration of ACT001 in China, South Korea, and Southeast Asian markets. SciGen has obtained overseas marketing rights for multiple products, including Abiraterone Acetate Tablets.
- **Product out-licensing:** TCM patent formulations such as Maqin Xiaoke Granules were exported to Singapore; Amikacin Sulfate Injection was exported to the European Union; Dinazone Oral Suspension was exported to Brazil; and Oxytocin Nasal Spray was licensed for overseas market registration and commercialization.

Amikacin Sulfate Injection Exported to Italy for the First Time

Ryzneuta® Shipped to the U.S. for the First Time

Special Topic I: Innovation Endures, Life Flourishes: R&D Breakthroughs and Health Commitments of Ryzneuta®

As a core innovative achievement in the biologics sector of Yifan Pharmaceutical, Efbemalenograstim Alfa Injection (English trade name: Ryzneuta®; Chinese trade name: 亿立舒®) is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) developed on the Company's proprietary DiKine™ dual-molecule platform. Its journey from R&D to global commercialization not only underscores the Company's technological breakthroughs and innovative capabilities in biopharmaceuticals but also exemplifies the seamless integration of clinical value realization, international expansion, and sustainable development practices. It is currently the only G-CSF therapeutic product worldwide that has conducted head-to-head clinical studies against both long-acting and short-acting innovator products, achieved pre-specified targets, and obtained marketing approval in countries or regions including China, the United States, Europe, and Brazil.

Upholding innovation to overcome global pharmaceutical technology challenges

The R&D of Ryzneuta® has consistently focused on addressing unmet clinical needs, breaking through industry bottlenecks through technological innovation. As the first G-CSF drug in China to achieve long-acting properties without polyethylene glycol (PEG) modification, its core technology lies in the use of Fc fusion protein technology. By genetically engineering the construction of human granulocyte colony-stimulating factor, it significantly extends the drug's half-life while maintaining high stability and bioactivity. This design inherently avoids the immune responses and hypersensitivity risks associated with traditional PEGylation modifications and effectively addresses the clinical challenges of frequent dosing and low patient compliance with traditional short-acting formulations.

Focusing on clinical value to safeguard treatment safety for cancer patients

The core clinical value of Ryzneuta® lies in its precise targeting of a critical unmet need in patients undergoing chemotherapy for cancer—neutropenia. While chemotherapeutic agents kill tumor cells, they also severely suppress bone marrow hematopoiesis, leading to a sharp decrease in neutrophil count, which significantly increases the risk of infection and may even interrupt the chemotherapy course, compromising treatment efficacy.

As a clinically recommended essential medication for elevating white blood cell counts, Ryzneuta® specifically stimulates the proliferation and differentiation of bone marrow hematopoietic stem cells, rapidly increasing peripheral blood neutrophil counts to effectively prevent and treat chemotherapy-induced neutropenia. Compared to traditional short-acting formulations, its long-acting design substantially reduces dosing frequency, significantly enhancing patient adherence. Additionally, through process optimization, it lowers the incidence of adverse reactions such as bone pain and myalgia. Notably, it remains effective in reducing the incidence of moderate to severe neutropenia during the third and fourth cycles of chemotherapy, demonstrating superior performance in elevating the absolute neutrophil count (ANC) nadir and shortening recovery time. Furthermore, its ability to achieve faster recovery of neutrophil levels when administered on the same day as chemotherapy provides greater flexibility for optimizing clinical treatment regimens and offers cancer patients a safer and more convenient therapeutic option.

Ryzneuta® received high recognition from global authoritative guidelines
The only domestically produced long-acting G-CSF included in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors (Version 1. 2025)
Included in the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines (2025)
Selected for poster presentation at the 116th Annual Meeting of the American Association for Cancer Research (AACR)
Selected for poster presentation at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO)
Successfully included in the NCCN Guidelines with a Category 2A recommendation
Included in Germany's "S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen" guidelines

In terms of medication safety, the prefilled syringe design of Ryzneuta® reduces operational complexity, accommodating diverse treatment scenarios and further expanding its clinical applicability, providing reliable support for standardized cancer treatment.

Special Topic I: Innovation Endures, Life Flourishes: R&D Breakthroughs and Health Commitments of Ryzneuta®

Dual breakthroughs in global expansion and sustainable development

The launch of Ryzneuta® marks a leap from “Innovation in China” to “global recognition”. In May 2023, the product received marketing approval from China's National Medical Products Administration (NMPA); in November 2023, it obtained marketing authorization from the U.S. Food and Drug Administration (FDA); in March 2024, it received marketing approval from the European Commission; and by the end of 2024, it received marketing approval from Brazilian Health Regulatory Agency (ANVISA), becoming the first domestically produced long-acting G-CSF product approved in China, the United States, Europe, Brazil, and other regions. It has since been incorporated into relevant clinical guidelines worldwide. In 2025, the NMPA approved a supplemental application for Ryzneuta® to change its dosing interval from 48 hours to 24 hours, the European Commission approved its self-administration application, and the Company's partner in Japan initiated research on even shorter dosing intervals. By the end of 2025, Ryzneuta® had established commercial partnerships in over 40 countries/regions globally, obtained approval in 36 countries/regions. In 2025, the first shipments in the U.S. market were completed in May. Fourteen new market partnership agreements were signed. Approvals were successfully obtained in Thailand and Malaysia, and marketing applications have been submitted in the Philippines, the United Arab Emirates, Albania, Vietnam, and other regions, with global commercialization accelerating steadily.

Grand Launch Ceremony of Ryzneuta® in China Held

Launch Timeline	Regions
May 2023	Obtained marketing authorization in China
November 2023	Secured approval for launch in the United States
March 2024	Obtained marketing authorization in the European Union
November 2024	Received approval for launch in Oman
December 2024	Obtained marketing authorization in Brazil
October 2025	Approved for launch in Thailand
November 2025	Secured approval for launch in Malaysia

In terms of social responsibility, Ryzneuta® was renewed for inclusion in the *National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2025 Edition)* in 2025, further advancing the Healthy China strategy and enhancing drug accessibility. The reimbursement criteria were expanded from patients who experienced severe neutropenia during their "previous" chemotherapy cycle to those who had experienced it during "any prior" cycle, broadening the coverage to benefit more clinical patients and significantly reducing their financial burden associated with medication.

At the same time, to optimize the overseas supply chain of Ryzneuta®, shorten product preparation lead times, and reduce supply costs, the Company actively filed with the U.S. FDA and the European EMA for the addition of new manufacturing sites for Ryzneuta® overseas formulations. It also carried out diversified patient education and clinical training activities around Ryzneuta®, improving standardized medication use among healthcare professionals and enhancing patients’ self-management capabilities, thereby building a comprehensive health protection system.

First Batch of Ryzneuta® Dispatched Nationwide

The R&D and practical application of Ryzneuta® vividly embody the "innovation and internationalization" strategy of Yifan Pharmaceutical, and serve as the core vehicle through which the company implements its sustainable development philosophy with technological innovation. From technological breakthroughs to the realization of clinical value, and from global outreach to sustainable development, Ryzneuta® not only offers tumor patients a superior treatment option but also establishes a benchmark image for biopharmaceutical companies in driving health and well-being through innovation and leading industrial development with responsibility. It injects strong impetus into the sustainable development of the global pharmaceutical and healthcare industry.

Special Topic II: Global Support, Local Empowerment: Building an Open and Collaborative Pharmaceutical Innovation Ecosystem

Against the backdrop of continuously upgrading global healthcare demands and the deep integration of industrial globalization, Yifan Pharmaceutical adheres to its mission of "striving to eliminate diseases for humans". With an open and collaborative core strategy, it has constructed a global business layout and innovation ecosystem. Through the simultaneous efforts of "bringing in" and "going global", supported by a multi-dimensional system and sustainable development practices, the Company has made steady progress in the global pharmaceutical market. It has not only achieved global business expansion but also demonstrated the responsibility and commitment of Chinese pharmaceutical companies.

Global layout: laying a solid foundation for diversified global commercial synergy

Rooted in the domestic Chinese market and targeting the global market for business expansion, the Company has established a global physical network covering R&D, production, and commercialization. This forms a global layout that integrates innovation generation, capacity assurance, and market access, laying a solid foundation for an open and collaborative ecosystem.

Global R&D network: Focusing on four major areas—biologics, small molecules, synthetic biologics, and specialty Traditional Chinese Medicine, the Company coordinates R&D teams across multiple regions. Through international multi-center clinical trials, it accumulates research data to provide core support for global product registration and commercialization. Global manufacturing system: The Company has built over ten production bases both domestically and overseas, all compliant with local pharmaceutical quality management standards, establishing a high-standard manufacturing system aligned with international norms. For core products, it has developed a global supply chain enabling cross-regional coordination of domestic bulk drug substance production and international fill-finish operations, ensuring stable global market supply. Global commercialization network: The Company's business covers multiple countries and regions, employing a diversified commercial model combining direct sales, distribution, and strategic partnerships. This creates a full-channel system covering both developed and emerging markets, providing solid support for global product distribution and patient services. Additionally, leveraging international conferences and platforms, the Company builds channels for global business collaboration and brand visibility, enhancing its global market access.

Global Layout of Yifan Pharmaceutical

Global resource integration: building an open and collaborative pattern of mutual empowerment

The Company adheres to a two-pronged cooperation strategy of "bringing in and going global", integrating high-quality global pharmaceutical resources with an open mindset. Focusing on key therapeutic areas such as hematological malignancies, solid tumors, orthopedics, and endocrinology, the Company works in tandem with its various business divisions to introduce clinical-stage or commercialized products while actively seeking overseas partners to expand the global market presence of its products. This approach aims to promote Chinese innovations on the world stage and build a mutually beneficial global cooperation ecosystem.

In terms of inbound cooperation, the Company focuses on addressing unmet global clinical needs by executing targeted product in-licensing and partnerships. During the reporting period, the Company obtained exclusive marketing rights in mainland China for Bayer's Stivarga® (Regorafenib Tablets) and Nexavar® (Sorafenib Tablets), as well as Biogen's Tecfidera™ (Dimethyl Fumarate). It also substantially finalized a cooperation agreement covering the production and commercialization rights for the investigational Class 1 innovative drug ACT001 in the treatment of small cell lung cancer brain metastases across core markets including China, South Korea, and Southeast Asia. Furthermore, the Company's wholly-owned subsidiary, SciGen, secured marketing rights for Nilotinib Capsules in Colombia and Central America, for Abiraterone Tablets in Mexico and Central America, for Dydrogesterone Tablets in the Philippines, and for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the Latin American market.

In terms of global expansion, the Company has significantly accelerated its pace of going global, achieving multiple breakthroughs in the overseas registration and commercialization of its domestic products. A marketing authorization application was submitted in Singapore for the Company's domestically marketed product, Norepinephrine Bitartrate Injection. Another domestically marketed product, Oxytocin Injection, successfully obtained approval for marketing in Tajikistan. Additionally, the Company's Italian subsidiary, Fisiopharma, achieved U.S. FDA approval for its Sugammadex Sodium Injection.

The Company's proprietary Traditional Chinese Medicine products manufactured in China—Maqin Xiaoke Granules, Ginkgo Biloba Pills, Piminxiao Capsules, and Dehumidifying and Anti-Itch Ointment, achieved first-time or repeat exports to Singapore, preliminarily establishing a pathway for TCM patent formulations in the Singaporean market. Amikacin Sulfate Injection, produced in China, was successfully shipped to the EU market, signifying that the Company's domestic chemical drug manufacturing quality system has been recognized as compliant with EU standards. The domestically manufactured proprietary product, Dinazone Oral Suspension, was urgently exported to Brazil, making the Company one of the few Chinese enterprises capable of supplying rare disease drugs to Brazil. Furthermore, a commercialization agreement was reached with Sygardis Rus, LLC for Oxytocin Nasal Spray, granting them the rights to register and commercialize the product in the Russian market.

The Company has strengthened global manufacturing certifications to solidify the foundation for product exports. During the reporting period, Hefei Yifan Biopharmaceutical successfully passed the PIC/S on-site inspection conducted by the Health Sciences Authority (HSA) of Singapore. Hefei Yifan Biopharmaceutical also obtained domestic packaging and distribution authorization for Euflexxa®. The Company's Italian subsidiary, Fisiopharma, achieved PMDA certification in Japan. As of the disclosure date of this report, certain of the Company's manufacturing sites have obtained GMP certifications from regulatory authorities in countries and regions including the United States, the European Union, Brazil, Singapore, Japan, and South Korea. The Company's global manufacturing quality system is now fully aligned with international standards, steadily advancing its transformation into a globally integrated pharmaceutical enterprise.

Looking ahead, Yifan Pharmaceutical will continue to deepen integration around the themes of "innovation, going global, and core business", constructing a three-tier product portfolio consisting of "star, growth, and defensive" products, while continuously expanding the boundaries of its global cooperation network. Guided by clinical needs, the Company will accelerate the overseas registration of its proprietary products and pursue two-way global business development (in-licensing and out-licensing). It will actively advance the deep cultivation of core products in overseas markets and the R&D of innovative products, continuously improving the global accessibility of its pharmaceutical offerings. The Company will promote international collaboration on biosimilar projects and further expand export channels for bulk drug substances and APIs. The Company will also focus on core therapeutic areas by actively in-licensing mature commercial products and exploring new growth drivers. Furthermore, Yifan Pharmaceutical will strategically build a differentiated and competitive pipeline of innovative drugs, establishing a multi-tiered, full-lifecycle product matrix to drive high-quality corporate development. It will further integrate the philosophy of sustainable development into the entire chain of its global operations, making sustained efforts in compliance-driven operations, green and low-carbon initiatives, employee rights protection, and charitable practices. Together with global partners, it aims to build a responsible, efficient, and co-developing global pharmaceutical innovation community, contributing its strength to global health causes through concrete actions.

By 2025, Yifan Pharmacy had achieved a critical leap from product globalization to ecosystem globalization. Through a China-rooted, globally-oriented network, resource integration that combines "bringing in and going global", strategic alignment with local flexibility in governance, and multi-dimensional sustainable practices, the Company has realized significant results in executing its globalization strategy. This has not only enhanced its global product portfolio and commercial footprint but also faithfully fulfilled its sustainable development commitments.



Yifan Pharmaceutical at Overseas Exhibitions



Global Supply Chain and Marketing System Layout of Yifan Pharmaceutical

01

SUSTAINABLE DEVELOPMENT MANAGEMENT

Sustainable development philosophy: safe, controllable, and sustainable development

Sustainable Development Management

(I) Sustainable development governance structure

Yifan Pharmaceutical upholds the core principle of synergistic development between economic and social benefits. While continuously providing high-quality products and professional services, the Company actively pursues pathways to sustainable development. To systematically plan, advance, and implement its sustainable development strategies, ensure orderly and effective sustainability management, and keep its operational strategy highly aligned with global sustainability trends, the Company has continuously optimized its top-down sustainable development governance structure with clearly defined roles and responsibilities. In 2025, it formally established the *Environmental, Social, and Governance (ESG) Management System*, providing a solid institutional foundation for advancing all related efforts.



Yifan Pharmaceutical's Governance Structure for Sustainable Development

(II) Stakeholder communication

Stakeholders	Key concerns	Means of response
Government/ regulatory authorities	Corporate governance Anti-bribery and anti-corruption Anti-unfair competition Environmental compliance management Technology ethics	Compliance with national laws and regulations Policy training and guidance Questionnaire surveys Visits and exchange visits
Shareholders/ investors	Corporate governance Due diligence Stakeholder communication	Official website Information disclosure Shareholders' meetings On-site research Performance briefings Investor communication
Employees	Employees	Employee representative congress Employee training and skills development activities Corporate culture activities Trade union activities Platform for rationalization proposals
Customers	Innovation-driven development Focus on rare diseases Universal health access Product and service safety and quality	Customer satisfaction surveys On-site visits Seminars and exhibitions Industry conferences
Suppliers	Supply chain security Equal treatment of small and medium-sized enterprises	Procurement negotiations On-site visits
Partners	Innovation-driven development Product and service safety and quality	Regular exchange meetings Regular visits Project team services Seminars and exhibitions Industry conferences
Public/ communities	Social contribution Rural revitalization	Public welfare activities Volunteer services Daily communication and interaction
Environment	Climate change response Pollutant emissions Ecosystems and biodiversity	Environmental declarations Monitoring disclosures Compliance filings

As the highest management and decision-making body for sustainable development, the Company's Board of Directors holds the core responsibilities of overall leadership and strategic decision-making. Based on management reports provided by the Sustainable Development Management Committee, the Board systematically analyzes potential risks and development opportunities in the sustainable development, provides strategic opinions on action plans and major initiatives related to sustainable development at the corporate level, guides the Sustainable Development Management Committee in implementing various decisions, and approves the Company's sustainability report to ensure its authenticity, completeness, and compliance.

To strengthen the oversight and management of sustainable development, the Company has established a Sustainable Development Management Committee at the management level. The Committee accurately assesses risks and opportunities in the sustainable development and promptly formulates response measures; based on the strategic decisions made by the Board, it develops specific management implementation plans for sustainable development and oversees the execution level to ensure results; it sets key performance indicators for sustainable development to facilitate the successful achievement of various sustainability goals and plans; and it organizes the preparation of the Company's sustainability report to ensure that the report quality meets relevant requirements.

The Company has established a Sustainable Development Executive Team as the specific implementing body for sustainability-related work. The Team coordinates the collaborative efforts of various business divisions and functional departments to carry out sustainability-related activities; strictly implements the work plans formulated by the Sustainable Development Management Committee and provides timely feedback on work progress, existing issues, and improvement recommendations; establishes a robust information and data collection system for sustainable development, regularly collecting and consolidating relevant information and data from all links. It promotes the deep integration of the sustainability concept into the Company's core business, integrating sustainability requirements throughout the entire business process; proactively identifies various risks and opportunities in the sustainable development, promptly communicates and addresses stakeholder concerns, and establishes an efficient communication and feedback mechanism; and completes the information collection, verification, compilation, and other related tasks for the Company's sustainability report to ensure the orderly progress of report preparation.

(III) Material topic analysis

As a publicly listed company on the Shenzhen Stock Exchange, Yifan Pharmaceutical consistently upholds the principle of collaborative win-win relationships with its stakeholders and actively builds a sustainable development ecosystem centered on enhancing social value. To comprehensively and accurately disclose the Company's sustainable development practices and achievements to both internal and external stakeholders, Yifan Pharmaceutical, based on its actual operations, conducts targeted stakeholder questionnaire surveys. Through online research, it extensively collects stakeholder requests and suggestions, identifies double materiality topics, determines their prioritization, and constructs a materiality matrix, ensuring that sustainable development efforts are responsively and effectively implemented.

Establishment of a topic library

Through benchmark research on standards, peer comparison, and an assessment of the Company's development status, internal and external material topics are identified to form a topic library. A total of 24 sustainability topics have been identified, including 5 corporate governance topics, 11 social topics and 8 environmental topics.

Stakeholder survey

Focusing on two dimensions—financial materiality and impact materiality regarding the sustainable development of Yifan Pharmaceutical, we invited stakeholders to rate the importance of each topic on a scale of 1 to 5.

Rating	Importance	Meaning
5	Very important	Immediate disclosure and management of this topic is necessary
4	Important	Disclosure and management of this topic is required
3	Somewhat important	Disclosure and management of this topic may be required
2	Less important	Immediate disclosure and management of this topic is not necessary
1	Not important	Disclosure and management of this topic is less necessary

In this survey, we collected a total of 545 valid questionnaires, covering the requests and suggestions of internal and external stakeholders, including government/regulatory authorities, shareholders/investors, employees, customers, partners, suppliers, and the public/community.

Stakeholder category	Number of questionnaires collected
Government/regulatory authorities	15
Shareholders/investors	32
Employees	436
Customers	24
Partners	8
Suppliers	15
Public/communities	15
Total	545

Topic analysis and prioritization

Through the dual perspectives of financial materiality and impact materiality, we conducted a comprehensive and in-depth statistical analysis of the collected survey questionnaires. Based on the analysis results, the materiality level of each topic was accurately prioritized, and a double materiality matrix was subsequently constructed.

Topic response and disclosure

Based on the results of the double materiality assessment, targeted disclosures are made in this report.

Yifan Pharmaceutical 2025 Sustainability Report Materiality Matrix



No.	Topic name	Financial materiality	Impact materiality	Other topics
1	Climate change response		●	
2	Pollutant emissions	●	●	
3	Waste treatment	●		
4	Ecosystem and biodiversity protection			●
5	Environmental compliance management	●	●	
6	Energy utilization	●	●	
7	Water resource utilization	●		
8	Circular economy	●		
9	Rural revitalization			●
10	Community contribution		●	
11	Innovation-driven development	●	●	
12	Technology ethics		●	
13	Focus on rare diseases	●	●	
14	Universal health access	●	●	
15	Supply chain security		●	
16	Equal treatment of small and medium-sized enterprises		●	
17	Product and service safety and quality	●	●	
18	Data security and customer privacy protection		●	
19	Employees		●	
20	Corporate governance	●	●	
21	Due diligence	●		
22	Stakeholder communication		●	
23	Anti-bribery and anti-corruption	●		
24	Anti-unfair competition	●		

In accordance with the requirements of the *Self-Regulatory Guidelines No. 3 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report* issued by the Shenzhen Stock Exchange, the Company has responded to the double materiality topics from the dual dimensions of "risks and opportunities", as detailed in the table below:

Double materiality topi	Category	Description	Countermeasure
Pollutant emissions	Risk	Improper disposal of wastewater, exhaust gas, and solid waste generated during production and operations may lead to excessive emissions, resulting in environmental penalties, compliance risks, and brand reputation damage.	Establish a whole-process pollutant control system; regularly monitor emission indicators; strictly enforce complian ce with emission standards; standardize hazardous waste disposal and record management.
	Opportunity	Promoting clean production and emission reduction technologies can lower environmental compliance costs, improve green production levels, align with the industry's low-carbon development trends, and enhance the green competitive advantage.	Promote energy-saving and consumption-reducing processes; carry out clean production transformation; advance resource recovery and reuse.
Environmental compliance management	Risk	Increasingly stringent environmental policies and rising regulatory standards may create compliance gaps if management is inadequate, leading to operational risks such as administrative penalties, production restrictions, or shutdowns.	Establish an environmental compliance management system; conduct regular self-inspections and training on environmental compliance; keep abreast of policy updates; implement statutory procedures such as environmental impact assessments and pollutant discharge permits.
	Opportunity	Strengthening the environmental compliance system helps improve the Company's standardized operations, meet regulatory and market requirements, and support the development of a green brand.	Build a whole-process environmental compliance management framework; establish a compliance risk early warning mechanism; strive to become an industry benchmark for compliance.
Energy utilization	Risk	Fluctuations in energy prices and inadequate energy consumption control may increase production costs. An energy-intensive operating model is inconsistent with low-carbon policy directions and poses energy efficiency control risks.	Implement renovation of key energy-using equipment; optimize the energy consumption structure; reduce comprehensive energy consumption per unit of product.
	Opportunity	Improving energy utilization efficiency and developing clean energy can lower operating costs, respond to the dual carbon goals, and secure policy support and green development dividends.	Promote the application of energy-saving technologies; gradually adopt green electricity and other clean energy sources; build energy-efficient production facilities.
Innovation-driven development	Risk	High R&D investment, long cycles, and uncertain success rates, coupled with insufficient breakthroughs in core technologies, may lead to declining product competitiveness and the risk of falling behind in technological iteration.	Increase investment in R&D funding and talent; establish mechanisms for tackling core technological challenges; strengthen intellectual property protection; build an R&D risk assessment system.
	Opportunity	Technological innovation and product upgrades can create core barriers, capture high-end markets, drive industrial upgrading, and align with the innovation-driven development of the pharmaceutical industry.	Establish industry-university-research collaboration platforms; focus on cutting-edge technology R&D; accelerate the translation of innovation into outcomes; continuously launch high-value-added innovative products and technologies.
Focus on rare diseases	Risk	High difficulty in R&D for rare disease drugs, small patient populations, and limited market coverage create uncertainty in the return on commercialization and R&D investment.	Precisely plan the rare disease pipeline; optimize R&D strategies; integrate clinical resources to reduce R&D uncertainty; expand the rare disease diagnosis and treatment service ecosystem.
	Opportunity	Strong national policy support for rare disease drug R&D and access, combined with significant market gaps, enables early movers to achieve differentiated competition and brand advantages.	Deepen R&D and introduction of rare disease drugs; participate in the development of rare disease diagnosis and treatment systems; build core competitiveness in the rare disease sector.
Universal health access	Risk	Limited profit margins for universal health products, coupled with intense market homogenization, create operational pressures in service coverage and cost control.	Optimize the universal product structure; strictly control costs and pricing; enhance large-scale operational capabilities; focus on grassroots and universal health scenarios for precise deployment.
	Opportunity	Rising national health demands and policies promoting universal health access help expand patient/user groups and fulfill social responsibilities.	Expand the supply of primary care and universal health products; advance health education and accessible services; leverage product down-market penetration to increase market coverage and brand influence.
Product and service safety and quality	Risk	The safety and quality of pharmaceutical products are directly related to patient health and life. Any quality defect may trigger recalls, penalties, litigation, and a major brand crisis.	Establish a full life-cycle quality control system; strictly comply with GMP and other standards; strengthen quality control of raw and auxiliary materials, process management, and finished product testing.
	Opportunity	Upholding the bottom line of quality and safety enhances customer trust and market recognition, builds a high-quality brand image, and creates a long-term competitive moat.	Implement a continuous quality improvement mechanism; strengthen the quality traceability system; win the market with high-quality products and services.
Corporate governance	Risk	The abolition of the supervisory board under the *Company Law* and the adjustment of internal oversight levels create risks such as poor coordination in oversight mechanisms, weakened supervisory functions, and gaps in internal control supervision.	Optimize the corporate governance structure; establish specialized bodies such as audit committees; strengthen supervisory functions; improve internal supervision and checks-and-balances mechanisms to ensure effective implementation of oversight responsibilities.
	Opportunity	Efficient and standardized corporate governance fosters more scientific decision-making, and enhances operational efficiency and risk resilience, earning recognition from capital markets and stakeholders.	Continuously optimize modern corporate governance mechanisms; strengthen integration with sustainable development governance; improve the quality of information disclosure; empower high-quality sustainable development through effective governance.

02

INNOVATION-DRIVEN RENEWAL OF PRODUCTS AND SERVICES

9 INDUSTRY, INNOVATION AND INFRASTRUCTURE

Contributing to Sustainable Development Goals (SDGs)

Governance

The Company, guided by its "innovation and internationalization" strategy, dynamically tracks policy changes, strengthens CMC research and clinical data management, and has established a full-industry-chain quality control system spanning from preclinical research to commercial production. Through lean manufacturing, domestic substitution, and process optimization, the Company continuously reduces costs and improves efficiency. Each business division has designated intellectual property management specialists responsible for coordinating global patent portfolios and IP risk prevention and control, thereby safeguarding the legitimate rights and interests of innovation outcomes.

Strategy

The Company adheres to an R&D strategy of "innovation-driven and differentiated competition", focusing on areas of unmet clinical needs, including oncology, metabolic diseases, and rare diseases, and has built a diversified product portfolio encompassing "innovative drugs, biosimilars, generics, specialty Traditional Chinese Medicine and synthetic biologics".

Risks and opportunities

Category	Specific content	Countermeasure
Regulatory risks	Stricter evaluation standards for drugs, more stringent filing requirements, and intensified inspections lead to extended R&D cycles, lower approval rates, and increased R&D costs, with some projects facing the risk of delay or termination.	Strengthen pharmaceutical and clinical data management, establish an R&D-registration linkage mechanism, dynamically track policy changes, adjust project priorities; continuously evaluate high-risk projects, promptly terminate low cost-effectiveness projects, and optimize resource allocation.
Market risks	The normalization of national volume-based procurement (VBP) compresses profit margins for generics, lowers development barriers, and intensifies market competition.	Avoid price wars on commodity drugs; expand into primary markets and private channels to offset sales volume gaps under VBP; accelerate global registration progress for biosimilars to seize market opportunities.
Policy support opportunities	National policies encourage the R&D of pediatric drugs and clinically urgently needed varieties, with potential for expedited review and favorable access to national reimbursement; green technologies such as synthetic biologics receive policy support.	Precisely align with national policy directions; optimize R&D pipeline layout; accelerate the R&D and filing of pediatric drugs; leverage synthetic biologics demonstration lines to advance product industrialization.

Objectives and targets

Total R&D investment:RMB **355 million** | Number of R&D personnel: **836** | Number of patent applications: **82** | Number of newly granted patents for the year: **28**

(I) Innovating for a healthier future

1. Product R&D innovation

Focus on R&D innovation

In 2025, guided by its "innovation and internationalization" development strategy, and with a core focus on "standardizing R&D processes, strengthening risk management and control, and improving decision-making efficiency", Yifan Pharmaceutical has built a diversified technology system centered on its core therapeutic areas, enabling the synergistic development of TCM, small molecule drugs, synthetic biologics, and biologics. In the TCM sector, the Company deepens its focus on traditionally advantageous diseases, systematically invests in innovative drugs and classic formulas, and continuously improves its product portfolio. In the small molecule drug area, it adopts an internal and external collaboration strategy, balancing improvement-driven innovation with a generic-innovative approach, steadily advancing product iteration and internationalization. The synthetic biologics segment has transitioned from capacity expansion to key technological breakthroughs and high-value-added transformation, striving to break away from homogenized competition. In the biologics sector, the Company pursues a dual-driver strategy of innovative drugs and biosimilars, covering the entire industry chain from preclinical research to commercial production. The diversified R&D pipeline and robust clinical and regulatory progress have laid a solid foundation for the Company's medium- to long-term development.

Product areas	R&D directions	R&D progress
Traditional Chinese Medicine	Focusing on TCM's traditional strengths in pediatrics and gynecology, with emphasis on developing innovative drugs and improved new drugs, while continuously enhancing the product portfolio.Focusing on TCM's traditional strengths in pediatrics and gynecology, with emphasis on developing innovative drugs and improved new drugs, while continuously enhancing the product portfolio.	The Phase III clinical trial of Fufang Yinhua Jiedu Granules for the treatment of pediatric influenza has been completed, and a registration application has been submitted; IIT clinical study of Compound Huangdai Tablets for the treatment of advanced recurrent platinum-resistant ovarian cancer: first subject enrolled and dosed, laying critical foundation for subsequent research; Phase Ib clinical trial of Duanjin Anti-Addiction Capsules (Class 1.1 new TCM drug) has been completed, achieving its expected objectives; We have completed the domestic manufacturing registration and marketing application for the classic formula Yi Huang Tang Granules.
Small molecule drugs	We adopt an "internal-external synergy" strategy for innovation. On one hand, we introduce products with clear clinical value and high synergy with our production lines. On the other hand, we rely on external technology platforms and innovative drug Contract Research Organizations (CROs) to advance early-stage R&D. For improved drugs, we focus on extending the lifecycle of key products based on clinical needs. Regarding generics, we focus on key areas such as high-potency anti-tumor drugs based on our existing pipelines and steadily advance the internationalization.	Eptazocine Hydrobromide Injection, Clenbuterol Hydrochloride Oral Solution, Cytarabine for Injection, Epirubicin Hydrochloride for Injection, and Isavuconazonium Sulfate for Injection have been approved for marketing; The Company has completed regulatory submissions to China's Center for Drug Evaluation (CDE) for Revefenacin Inhalation Solution and Vinorelbine Tartrate Injection.
Synthetic biologics	Building on successful upstream and downstream integration and notable market development achievements, we are shifting from capacity expansion to tackling key technological challenges, extending industrial chains, and transitioning to high-value-added operations, aiming to break through homogeneous competition and continuously enhance core competitiveness.	The vitamin B6 project has completed production line installation and is currently in the phase of pressure testing, leak testing, and water run-in; The Human Milk Oligosaccharide (HMO) 6'-SL has been submitted for registration to China's National Health Commission (NHC) and has obtained FDA SELF-GRAS certification in the United States; The Human Milk Oligosaccharide (HMO) 2'-FL has obtained FDA GRAS certification in the United States and has received approval from China's National Health Commission (NHC).
Biologics	Synthetic biologics Focusing on core therapeutic areas such as oncology and metabolism, building a dual-drive R&D system of "innovative drugs + biosimilars" that covers the entire industrial chain from preclinical research to commercial production.	Biosimilar pipeline: Clinical trial approval notices have been received for Insulin Glargine Injection and Human Growth Hormone Injection. Innovative drug pipeline: Project F-652 has obtained the approval notice for the Phase II clinical trial in China for the treatment of acute Graft-versus-Host Disease (aGVHD); Project N-3C01 has obtained the clinical trial approval in China for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer.

Yifan Pharmaceutical R&D Overview in 2025

TTotal R&D investment RMB **355 million**

R&D as percentage of pre-tax revenue **6.91%**

Number of R&D personnel **836** persons

Case: Yifan Pharmaceutical International Innovation Centerofficially launches—building a core engine for global innovation and R&D

In 2025, Yifan Pharmaceutical International Innovation Center was officially inaugurated in Shanghai. Nearly two hundred on-site guests and numerous online partners jointly witnessed this significant moment, marking a new milestone in the Company's innovation and international development. The opening ceremony blended technology with tradition: a robotic dance performance showcased the allure of cutting-edge technology, while a traditional lion dance symbolized the auspicious beginning of new opportunities and the aspiration to reach new heights—a vivid reflection of the Company's dynamic and diversified development.

As the core hub of the company's R&D system, the launch of Yifan Pharmaceutical International Innovation Center represents a solid step forward in the Company's pursuit of innovative drug R&D and global expansion. In the future, the center will adopt an open approach to integrate global R&D resources, maintain a forward-looking vision to focus on cutting-edge technologies, and foster a collaborative spirit to build an efficient innovation platform. It is committed to becoming a hub of wisdom and an accelerator for new drug development, serving as the core engine for the Company's technological achievement transformation and continuously contributing Yifan's strength to global human health.

Yifan Pharmaceutical International Innovation Center Established in Shanghai

Case: Yifan Pharmaceutical 2025 R&D Conference—embracing the "Refining Era" with perseverance

In November 2025, Yifan Pharmaceutical held its annual R&D conference with the theme of "Global Development, Boundless Innovation". The conference focused on the main themes of "innovation and internationalization", conducting in-depth analyses of policy and technological frontiers such as accelerated drug approval pathways and AI-driven drug regulation. Concurrently, internal reviews were conducted on topics including cost reduction and efficiency improvement, generic drug Volume-Based Procurement (VBP) strategies, and talent incentives.

The Company’s founder stated that the pharmaceutical industry has transitioned from the “Gold Rush Era” to the “Refining Era”, and that Yifan Pharmaceutical aspires not to be a follower, but a courageous and persistent contender. The Conference further strengthened the cultural and strategic foundation for deepening the Company’s global R&D footprint and bringing Chinese innovations to patients worldwide.

Intellectual property protection

We attach great importance to the management and protection of intellectual property rights, strictly adhering to relevant laws and regulations such as the *Patent Law of the People's Republic of China, the Trademark Law of the People's Republic of China,* and the *Anti-Unfair Competition Law of the People's Republic of China*. In February 2025, the Company successfully completed the recertification to the updated *Enterprise Intellectual Property Compliance Management System* (GB/T 29490) and obtained a new certificate, ensuring ongoing compliance and best-in-class system operation.

In 2025, the Company experienced no intellectual property disputes or issues.

Intellectual property management	
Newly granted patents	28
Among them, granted invention patents	13
Granted utility model patents	15
Cumulative granted patents	294
New patent applications	82
Among them, applied invention patents	51
Applied utility model patents	31
Cumulative applied invention patents	272

2. Empowerment through technological innovation

Refining the top-level desian

To systematically advance digital transformation, the Company has formulated a phased strategy of "strengthening the foundation, streamlining processes, and empowering all employees", enabling digitalization to permeate from point solutions to enterprise-wide integration:

① Full-chain coverage: Centered on the integration and rollout of the ERP system, we have connected core business processes including finance, supply chain, and sales, achieving closed-loop and real-time synchronization of key data flows, thereby laying the foundation for refined operations.

② Full-scenario integration: By implementing digital office solutions and digital business travel management, digital tools have been embedded into high-frequency scenarios such as daily office work and travel approvals, enhancing collaboration efficiency and employee experience.

③Omnidirectional interaction: The launch of the “Channel Lifecycle Management” project has significantly improved order processing efficiency—achieving a 99% channel order coverage rate, 99% accuracy in payment notification delivery, and 99% payment reconciliation accuracy, substantially reducing operational costs.

Strengthening talent development

① Cultivating enterprise-wide digital literacy: To establish digital capability as a core competency for all employees, we have systematically conducted multiple rounds of online and offline training sessions and "Skills Bootcamps" focused on daily office software, covering over 260 person-times. Training goes beyond functional explanations to include scenario-based hands-on guidance, such as multi-dimensional spreadsheet creation and automated workflow design. This approach helps employees directly translate digital tool proficiency into practical solutions for real business challenges, infusing grassroots momentum into the digital transformation.

② Building Specialized Technical Capabilities: We adhere to the principle of “learning by doing and honing expertise through practice.” Key projects such as the “System Integration Platform” serve as core practical training grounds. Through structured technical training and project-based problem-solving, we have enabled the IT development team to master core technical capabilities including low-code interface development, data integration, and API governance.

Currently, the team has achieved efficient, independent interface development capabilities, with an overall development efficiency improvement exceeding 50%. This has not only significantly reduced reliance on external resources but has also substantially built an internal digital middleware capability foundation, providing solid technical support for the Company's future business expansion and innovative applications.

Promoting service innovation

① Accelerating process innovation: By introducing RPA (Robotic Process Automation) solutions, we have automated data collection, payment notifications, and receipt printing, freeing employees from repetitive tasks. This has directly reduced operational costs while improving process accuracy and processing efficiency.

② Responding to business needs: Leveraging the YiDa low-code platform, we have rapidly developed and deployed personalized lightweight applications such as weekly report management and customer visit tracking, promoting the digitalization, standardization, and data accumulation of business processes. This “agile and flexible” approach supports micro-innovation in business models.

3. Adherence to technology ethics

Throughout the Company's drug clinical R&D process, we strictly comply with national laws, regulations, and industry standards. All clinical trials are conducted only after obtaining approval from the drug regulatory authority and passing ethics committee review. Our protocol design consistently adheres to the principle of "quality by design," ensuring the scientific validity, reliability, and operational feasibility of each trial.

We place the highest priority on protecting the rights and interests of trial subjects, making this a primary consideration throughout the R&D process. Each subject is required to sign an Informed Consent Form in accordance with relevant regulations, ensuring that clinical trial procedures are standardized and data is reliable.

In 2025, the Company experienced no violations of technology ethics.

(II) Advancing accessible healthcare

1. Focus on rare diseases

In the rare disease field, we continuously optimize production processes and rationally manage costs to fill therapeutic gaps in pediatric rare diseases in China while effectively reducing the financial burden on patient families, ensuring that innovative outcomes truly benefit the public. As the first company in China to receive approval for Dinazone Oral Suspension, Yifan Pharmaceutical has not only filled the gap for a first-line treatment for Congenital Hyperinsulinism (CHI), a pediatric rare disease, but has also improved the level of rare disease care by enhancing drug accessibility, safeguarding the well-being of countless families. Building on its in-house R&D capabilities, the Company has secured exclusive marketing rights for the original rare disease drug Tecfidera™ in Mainland China, actively establishing a two-way “bringing in and going global” channel, thereby further enriching its rare disease product portfolio.

Meanwhile, we actively fulfill international health commitments. Through close collaboration with medical institutions, promoting broad coverage of rare disease diagnosis and treatment services across all levels of society. Yifan Pharmaceutical consistently prioritizes enhancing the accessibility of rare disease drugs as a key direction in our R&D and in-licensing efforts. Leveraging our professional expertise and resource advantages, we strive to safeguard the equitable health rights and interests of rare disease patients, enabling more people to share a healthier future.

Focusing on Pediatric Rare Diseases: Yifan Pharmaceutical Featured at the National Annual Conference on Pediatric Endocrinology, Genetics and Metabolism

Case: focusing on pediatric rare diseases—Yifan in action

In February 2025, the "CHI Pathway: Multidisciplinary Health Education Program for Congenital Hyperinsulinism", exclusively sponsored by Yifan Pharmaceutical, was successfully held on the People's Daily Health Client platform. During the event, experts systematically interpreted the clinical value of Dinazone Oral Suspension—the only first-line CHI treatment in China, developed by Yifan Pharmaceutical, and answered questions from parents of affected children online. The program attracted over 400,000 online views from medical professionals and parents of children with CHI.

As the first pharmaceutical manufacturer to fill this treatment gap in China, Yifan Pharmaceutical actively advanced the standardization of CHI diagnosis and treatment by supporting this educational initiative, helping to bring quality medical resources to more families affected by rare diseases.

Public Health Education Lecture Events

Yifan Pharmaceutical Product Information Statistics	
Proprietary varieties	21
Proprietary dosage form products	12
Proprietary strength products	4
Proprietary NRDL products	18
Proprietary National Essential Medicines List products	5
National secondary protected Traditional Chinese Medicine varieties	1
TCM products included in the WHO Model List of Essential Medicines	1

2. Medical accessibility

We are always committed to enhancing patient access to medicines globally. By pursuing a multi-pronged strategy encompassing national reimbursement listing (NRDL), participation in Volume-Based Procurement (VBP), and international expansion, we achieve synergistic growth of corporate and social value.

Inheriting and innovating TCM to contribute China's solutions. The Company holds 108 TCM product varieties, including 14 proprietary products listed in the National Reimbursement Drug List (NRDL). These include well-known products such as Compound Huangdai Tablets, Xiao'er Qingqiao Granules, Dehumidifying and Anti-Itch Ointment and Fufang Yinhua Jiedu Granules. Yifan Pharmaceutical is among the domestic pharmaceutical companies with a significant number of proprietary products, particularly those included in the NRDL or the National Essential Medicines List. Compound Huangdai Tablets, a specific and effective treatment for acute promyelocytic leukemia (APL), had its molecular mechanism research published in the *New England Journal of Medicine,* a leading international journal, and received the Second Prize of the National Award for Scientific and Technological Progress. This product is not only recommended by China's APL diagnosis and treatment guidelines but has also been included in the expert consensus of the European LeukemiaNet (ELN). It stands as one of the few TCM products listed on the WHO Model List of Essential Medicines, bringing Chinese innovation to patients worldwide.

Compound Huangdai Tablets

Clear heat and remove toxins, supplement Qi and generate blood, for the treatment of newly diagnosed acute promyelocytic leukemia.

A proprietary drug in the NRDL and a product in the WHO Model List of Essential Medicines

Fufang Yinhua Jiedu Granules

Dispel wind and release the exterior, clear heat and remove toxins, for the treatment of common cold and influenza with wind-heat syndrome.

National category III new Traditional Chinese Medicine, national secondary protected Traditional Chinese Medicine variety, included in the NRDL and the National Essential Medicines List

Domestically, universal healthcare continues to be implemented. The core product, BDDE-Crosslinked Sodium Hyaluronate Injection, has successfully been renewed for inclusion in the 2025 National Reimbursement Drug List (NRDL), which not only enriches clinical medication options but also facilitates the allocation of high-quality medical resources to grassroots levels through the “Dual-Channel” policy. Under public oversight, it ensures reasonable returns in underserved markets. Several of our key products maintain the NRDL eligibility, strengthening market competitiveness while demonstrating the value of universal healthcare by effectively reducing patients’ medication costs. In Volume-Based Procurement (VBP) practices, the Company actively responds to national policies to promote winning the product selection, rapidly expanding market coverage through “volume-driven pricing” strategies. This not only fulfills the social responsibility of a private enterprise but also achieves sustainable operations through economies of scale.

BDDE-Crosslinked Sodium Hyaluronate Injection(Euflexxa®)

It is indicated for adult patients with knee osteoarthritis (OA) who experience inadequate pain relief from non-pharmacological conservative treatments and simple analgesic therapy (e.g. acetaminophen).

Imported product, NRDL negotiated drug product

Norepinephrine Bitartrate Injection

Used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, sepsis, blood transfusion, and drug reactions). Serves as an adjunctive treatment for cardiac arrest and severe hypotension. For shock due to hypovolemia, this product is used as an adjunct to emergency volume replacement to raise blood pressure and temporarily maintain cerebral and coronary artery perfusion until volume replacement therapy takes effect. It may also be used to maintain blood pressure following resuscitation from cardiac arrest.

NRDL product, Volume-Based Procurement (VBP) product

Internationally, the global layout is steadily advancing. Leveraging its well-established sales networks and industrial hubs across Europe, the United States, Japan, South Korea, and Southeast Asia, the Company is deepening its expansion into ASEAN and African markets, promoting the internationalization of Chinese pharmaceutical products. Currently, the Company has established an extensive commercial network in more than 50 countries and regions, including Singapore, South Korea, Italy, Germany, and the United States, enabling high-quality domestic drugs to reach global markets.

Efbemalenograstim Alfa Injection (Ryzneuta®)

It is indicated for the prevention of neutropenia in cancer patients following chemotherapy.

It is the first innovative biotech drug in China whose Marketing Authorization Holder (MAH) has obtained regulatory approvals in China, the United States, the European Union, and other countries.

Dinazone Oral Suspension

It demonstrates significant efficacy in treating hypoglycemia associated with insulinoma/hyperinsulinemia, with good safety and tolerability, and is recognized as the preferred/ first-line treatment.

(III) Maintaining strict safety standards

1. Work safety management

The Company thoroughly implements the *Work Safety Law of the People's Republic of China*, shouldering full responsibility for work safety, and systematically enhancing the safety management system. We prioritize safety as central to our development strategy, implementing regular risk checks, standardized equipment maintenance, safety education, and practical emergency drills. These efforts continuously strengthen the foundation of safety management, effectively ensuring the safety of employees and the stable operation of the enterprise.

Safety risk control

In 2025, the Company kept optimizing its safety risk control mechanism based on specific circumstances: Evive Biotechnology (Beijing) has finished reassessing safety risk classifications, devised specific control measures; Hunan Furong Pharmaceutical conducted regular inspections of firefighting facilities; Suzhou Yifan Pharmaceutical improved risk control through external expert reviews; Sichuan Defeng Pharmaceutical carried out 81 safety inspections throughout the year, identifying 109 hazards with a rectification rate of 96.4%, and allocated RMB 10,502.6 in special funds for hazard remediation; Sichuan Kaijing Pharmaceutical established and operationalized a dual prevention system for graded risk control and hidden hazard investigation and management; Liaoning Yifan Pharmaceutical updated internal systems based on dynamic risk assessments, identifying and rectifying 41 hazards throughout the year with a 100% rectification rate.

Meanwhile, Hefei Yifan Biopharmaceutical continuously updated and refined the *Risk Control List* and the *"Dual Prevention Mechanism" Management Manual for Work Safety,* forming a systematic risk management framework. In daily operations, in-depth hidden hazard investigations and remediation were conducted, including regular, pre-holiday, and special inspections throughout the year. Identified issues underwent qualitative analysis, root cause tracing, and closed-loop rectification, achieving a 98% rectification rate, and no major safety hazards were discovered. These efforts effectively ensured controllable safety risks for the Company.

The Safety Committee of the Biologics Business Division Regularly Organizes Work Safety Meeting

The Company Organizes Work Safety Training

Key Safety Officers of the Biologics Business Division Lead Teams in Inspection

Work safety awareness campaigns

In 2025, while continuously improving the risk control system, we vigorously promoted transforming the safety philosophy from “passive compliance” to “internalization”. Subsidiaries and factories, based on actual production conditions, carried out diverse and extensive safety awareness education activities, embedding safety consciousness into the daily behaviors of all employees.

The Company systematically advanced annual safety training and publicity initiatives as planned, including regular special training on occupational health and fire safety and the “Three-Level Safety Education” for new employees. At the same time, leveraging platforms such as “Work Safety Month” and “Fire Safety Month”, the company fostered a positive environment where everyone learns and advocates safety through diverse activities including training sessions, competitions, and drills, effectively enhancing employees’ safety awareness and emergency response capabilities.

Company Name	Safety Promotion Measures
Hunan Furong Pharmaceutical	Centered on the “Safety Month” theme, the company organized specialized training, high-temperature protection campaigns, and heatstroke emergency drills to enhance employees’ ability in seasonal risk prevention.
Tianchang Yifan Pharmaceutical	The company developed the *Work Safety Knowledge and Competency Handbook* and carried out targeted promotional training to ensure safety knowledge is thoroughly understood and internalized.
Suzhou Yifan Pharmaceutical	The company integrated safety promotion throughout the year, continuously carried out the “Five ONEs” knowledge spot checks to reinforce employees’ safety awareness.
Sichuan Defeng Pharmaceutical	The company innovatively implemented a behavior safety incentive program and organized on-line fire safety knowledge competition, achieving a participation rate of 81%, effectively boosting learning enthusiasm of employees.
Sichuan Kaijing Pharmaceutical	Leveraging special periods such as Safety Month, Fire Safety Month, etc., the company conducted centralized thematic publicity and practical drills to strengthen the emergency response capabilities of all employees.
Liaoning Yifan Pharmaceutical	The company established a diversified publicity matrix and successfully organized a series of activities for “Work Safety Month”, embedding safety awareness deeply into the corporate culture.

The Sixth “Work Safety Month” Activity of the Small Molecules (TCM) Business Division

Anqing Xinfu Organizes Fire Emergency Drill

Evive Biotechnology (Beijing) Organizes Work Safety Emergency Drill

2. Upholding the original aspiration for quality

Yifan Pharmaceutical has always regarded product quality as the legal cornerstone and moral baseline for the Company’s development. We fully implement the primary responsibility for product quality, strictly comply with laws and regulations such as the *Drug Administration Law of the People’s Republic of China* and its implementing regulations, and establish a quality control system covering the entire production process. We are deeply aware that every pill carries the trust of patients for life. Therefore, we continuously strengthen the management of key aspects and processes of drug quality. In 2025, the Company did not experience any major safety or quality liability incidents related to products or services.

Yifan Pharmaceutical Formulation Management Center launched the “Quality Improvement Special Initiative”, establishing a unified quality policy of “Quality as the Foundation, Innovation for Adaptation, and Pursuit of Excellence”, which was officially implemented since September 1, 2025. Centered around this policy, subsidiaries organized and carried out quality knowledge competitions, deepened self-inspection and self-correction risk controls, and combined these efforts with the internal “Quality Month” activities. These initiatives effectively enhanced the quality awareness and management level, led to the certification under PIC/S regulations, further solidified the quality culture atmosphere, and injected sustained momentum into the effective operation of the quality system.

In 2025, the Formulation Management Center’s first-pass qualification rate remained above 99.9%, while the market sampling qualification rate has consistently reached 100% for consecutive years.

Organizing Quality Knowledge Competitions

Case: Xinzhu Plant introduces Kanban management, leveraging "Visualization" to enhance both quality and compliance

Since its establishment, the Xinzhu Plant has been systematically building a comprehensive quality management system aligned with business development needs. This system covers six key areas: Quality, Production, Materials, Facilities & Equipment, Laboratory, and Packaging. To address increasingly diverse operational scenarios, the plant's teams innovatively introduced the "+QDCI Kanban Management" mechanism, which includes six modules: EHS (+), Quality Management (Q), Delivery of Results (D), Cost Control (C), All Employees Involvement (I), and Hot Topics. This approach enables full visualization of management elements.

- 01 +QDCI Kanban Management" mechanism EHS (+)
- 02 Quality Management (Q)
- 03 Delivery of Results (D)
- 04 Cost Control (C)
- 05 All Employees Involvement (I)
- 06 Hot Topics

Since the implementation of Kanban management and morning meeting mechanisms, the QA team has routinely conducted cross-departmental surprise inspections, delving deep into the production frontlines to directly observe operational processes, equipment performance, and material flow. This approach has enabled the precise identification of numerous hidden issues that are difficult to detect through office reports. Visible and transparent management has made quality control more robust and actionable.

Kanban morning meeting of QA team

Quality culture debate competition organized by QA team

Case: GembaWalk team drives quality management enhancement through routine inspections

The Biologics Business Division established a dedicated GembaWalk team to encourage managers to step out of their offices and engage deeply with the production frontlines, confronting the actual conditions of operational processes, equipment performance, and material flow. Through on-site observation and cross-departmental collaboration, the team accurately uncovers latent issues that are often invisible in report data. This not only helps the management break down information barriers and grasp on-site realities but also builds bridges of communication and trust among employees at different levels.

Since its establishment, the GembaWalk initiative has demonstrated significant results across multiple dimensions, including compliance strengthening, risk reduction, process optimization, employee empowerment, and the deepening of quality culture. Routine on-site supervision keeps all employees consistently vigilant about compliance, internalizing high-standard behavioral norms as daily habits, thereby solidifying the dual defenses of product quality and work safety.

The QA team collaborated with various departments to discuss solutions for issues identified by the GembaWalk team.

3. Drug recall management

The company strictly complies with regulatory requirements such as the *Drug Administration Law of the People's Republic of China, Good Manufacturing Practice for Drugs, and Drug Recall Management Measures,* and has established a robust product recall system. Each manufacturing site under the Preparation Production Center has developed Drug Recall Management Procedures, creating a coordinated institutional framework from top to bottom.

In 2025, the Company did not experience any actual product recall incidents. Through regular simulated recall drills, the operability and effectiveness of the recall procedures were fully validated, demonstrating the Company's rapid response capability to potential product issues and its well-established product traceability system.

Case: Yifan Pharmaceutical organizes simulated recall drill for Capecitabine Tablets

On September 25, 2025, the Small Molecules (TCM) Business Division organized an emergency drill for product safety incidents to test the execution and response efficiency of the active recall procedure. Using Capecitabine Tablets as the simulated object, the drill was initiated without prior notice at 7:30 a.m., fully simulating the entire process from incident reporting and recall instruction issuance to information tracing.

This batch of product involved a total shipment of 48,975 boxes distributed to 38 partners across 16 provinces (autonomous regions) nationwide. On the launching day, the Quality Assurance Department completed the preparation of the recall notice, while the Sales Department and Logistics Department simultaneously initiated customer notifications. The Information Department publicized the recall information on the official website. By September 29, all finished product inventory and drug distribution information had been fully traced and compiled, successfully completing the simulated recall task.

Product Recall Simulation Drill Site

03

COLLABORATION FOR MUTUAL SUCCESS AND VALUE CREATION

Contributing to Sustainable Development Goals (SDGs)

Governance

Each business division is responsible for overseeing supplier admission, evaluation, grading, and exit management. Relevant divisions formulate supplier management policies, review major procurement matters, and supervise compliance within the supply chain. In customer service, the divisions coordinate complaint handling, customer satisfaction surveys, and service process optimization to ensure effective protection of customer rights.

Strategy

Guided by the principle of “Openness for Mutual Benefit, Collaboration for Long-term Success”, the Company is committed to building a responsible and sustainable supply chain ecosystem and customer service system. In the supply chain domain, a green supplier selection mechanism is implemented, prioritizing partners with strong environmental compliance and social responsibility. Localized procurement is deepened to enhance supply chain resilience and responsiveness, while integrity management is strengthened to foster a transparent and fair cooperation environment. In customer service, a “Professional, Transparent, and Efficient” system is established, leveraging multi-channel communication platforms, a three-tier complaint handling mechanism, and customer satisfaction follow-ups to continuously improve customer experience and satisfaction. Additionally, the Company actively fulfills social responsibilities by leveraging its professional expertise to support the health and public welfare initiatives of the community.

Risks and opportunities

Category	Specific content	Countermeasure
Supply chain disruption risk	Dependence on single-source suppliers, geopolitical conflicts, natural disasters, etc. may lead to interruptions in the supply of critical materials, affecting production continuity and delivery capabilities.	Implement dual/multi-source supply strategies to reduce reliance on single suppliers; establish a supplier alternative database and regularly assess supply risks; strengthen inventory management to ensure safe reserves of critical materials.
Customer trust risks	Issues such as product quality problems, delayed complaint handling, and privacy breaches may undermine customer trust, affecting brand reputation and market share.	Enhance the quality management system to ensure product safety and efficacy; optimize complaint handling processes to improve response speed and customer satisfaction; strengthen data security protection to prevent privacy breaches.
Localized procurement opportunities	Implementing localized procurement can shorten supply cycles, reduce procurement costs, and simultaneously drive regional economic development while strengthening government-enterprise partnerships.	Develop regional resource maps to identify key procurement areas; promote the “direct sourcing from production areas” model to streamline intermediate processes; cultivate local potential suppliers to achieve win-win cooperation.

Objectives and targets

Number of suppliers signing integrity commitments: **1,931**	Number of customer complaints: **467**	Customer complaint response rate: **100%**	Customer privacy breaches or theft-related security incidents: **0**	Total investment in public welfare activities: RMB **6.0176 million**

(I) Supply chain management

1. Supplier management system

Supplier admission mechanism

Based on product development, approval, and production progress, the Company identifies required raw materials, excipients, and packaging materials. The quality management department establishes corresponding quality standards and screens potential suppliers according to system requirements. After passing qualification review, suppliers provide samples, which are jointly evaluated by the Quality Management Department and the product-related department for suitability. Upon successful sample validation, the Procurement Department and Quality Management Department conduct a new supplier admission assessment, focusing on production environment, quality control systems, and environmental risks. On-site audits are performed when necessary. Suppliers meeting environmental and quality requirements are included in the Approved Supplier List.

For suppliers requiring on-site audits, the regular audit frequency is once every two years. If the supplier receives an grade A in two consecutive on-site audits, the frequency may be adjusted to once every three years. If subsequent audit results fall below grade A, the frequency reverts to once every two years (audit methods may be adjusted flexibly based on actual conditions). For suppliers not subject to on-site audits, if major quality indicators of their products show abnormal fluctuations, targeted audits shall be initiated promptly to ensure ongoing stability of the supply chain quality.

The Small Molecules (TCM) Business Division has established the *Supplier ESG Admission Standards*, making environmental facility acceptance and carbon footprint verification mandatory requirements. Differentiated criteria are applied: suppliers of Chinese herbal medicines and prepared slices must possess “fresh processing” qualifications and provide certificate of genuine medicinal materials, records of pesticide and fertilizer usage, and test reports confirming compliance for pesticide residues and heavy metals. Chemical drug ingredient suppliers must submit GMP certification and associated review qualification documents. Companies found to be non-compliant with environmental standards, violating labor regulations, or associated with negative information will be subject to an immediate exit mechanism upon verification.

Tiered management and control of suppliers

To achieve refined management of suppliers, the Small Molecules (TCM) Business Division has established a scientific supplier risk assessment system. Through annual dynamic tracking, evaluation, and classification, it ensures the continuous stability of the supply chain quality. The evaluation system covers six core dimensions, including qualification compliance, quality stability, and traceability capability, and introduces ESG weighting scores: Environment (50%, including carbon emissions, energy efficiency, waste management, and environmental compliance), Social (30%, including employee rights, work safety, community responsibility, and supply chain management), and Governance (20%, including compliance management, transparency, business ethics, and risk control). Based on the comprehensive score, suppliers are classified into three levels—Grade A (Excellent), Grade B (Satisfactory), and Grade C (Restricted)—for dynamic management and tiered responses.





Meanwhile, the business divisions categorize suppliers into a three-tier supplier echelon based on the importance of product categories, establishing differentiated access and assessment systems:

Excellent suppliers	Suppliers that directly impact the core product competitiveness and supply chain security of the Business Division's core products, involving patented APIs, exclusive APIs (including monopolized supplies), exclusive excipients, and critical pharmaceutical packaging materials (sterile/injectable). These suppliers are eligible for priority order allocation, long-term framework cooperation agreements, priority participation in new product collaboration and price negotiations, and regular strategic cooperation communications to jointly improve quality and supply efficiency, and reduce the costs.
Satisfactory suppliers	Suppliers with relatively stable quality and cost advantages, including suppliers of packaging materials, consumables, and other related materials.
Restricted suppliers	Suppliers of general non-production materials and emergency backup suppliers.

In 2025, supply chain resilience continued to strengthen, with the proportion of excellent and satisfactory suppliers increasing to **70%,** and the supply assurance capability for critical materials being significantly consolidated. Specifically, the on-time supply rate for Chinese medicinal materials and medicinal slices reached **99%**, and the supply stability for chemical drug ingredients reached **98%**. There was no production interruptions caused by supplier issues throughout the year, and no compliance risk incidents such as environmental penalties or labor disputes among cooperating suppliers. The overall supply chain operation remained stable and controllable.

Supplier integrity management

The Company conducts regular assessments of supplier performance and continuously strengthens the management of the entire supply chain process. In terms of anti-corruption and anti-bribery, in accordance with internal regulations such as the *Anti-Commercial Bribery Compliance Management System* and relevant national laws and regulations, anti-corruption clauses, definitions of violations, and reporting hotlines are explicitly included in contracts and bidding documents. Additionally, the Company signs *Anti-Commercial Bribery Agreement* with suppliers to enforce constraints from the institutional source. The Company's office automation (OA) portal provides online and QR code-based reporting channels, offering rewards and strict protection to reporters while firmly resisting any form of retaliation. This ensures unimpeded supervision channels and timely feedback, establishing a comprehensive supervision mechanism covering pre-event, in-process, and post-event phases.

To strengthen integrity and compliance management in the supply chain, the Company implements a tiered approach to handling supplier violations:

- For minor violations, written warnings will be issued, requiring the submission of a compliance rectification report within 10 working days; all procurement and custom R&D cooperation related to small molecule Traditional Chinese Medicine will be suspended until acceptance is approved; 10%–20% of the performance bond will be deducted, and the violation will be recorded in the integrity file.
- For serious violations, all cooperation will be terminated immediately, with full compensation for economic losses required, illegal gains recovered, and the supplier blacklisted by the company and within the industry, with notifications circulated industry-wide.

Simultaneously, an internal coordinated accountability mechanism will be established. Employees involved in colluding with suppliers for bribery will be subject to penalties such as demotion or dismissal, depending on the severity of the offense. Cases involving suspected job-related crimes will be referred to judicial authorities, with results publicly disclosed to serve as a deterrent, ensuring the implementation of "investigating and punishing every identified case".

2. Sustainable supply chain

Screening green suppliers

Establishing a green supplier standard system. The Small Molecules (TCM) Business Division has formulated the “Green Supplier Grading Standards”, which explicitly require suppliers to obtain ISO 14001 Environmental Management System certification. The target is for green suppliers to account for **75%** of the total by 2026. This year, five suppliers failing to meet environmental standards have been phased out. Additionally, priority is given to procuring Chinese medicinal materials that are GACP (Good Agricultural and Collection Practices) certified, organically certified, or cultivated through ecological farming practices, ensuring environmental friendliness from the source.

Strengthening the access and dynamic evaluation mechanism. The Small Molecules (TCM) Business Division issues the Green Supply Chain Management Standards, incorporating the “Environmental Compliance Commitment Letter” and product environmental attributes into the criteria for new supplier admission. A dedicated “Green Performance” category, weighted at **20%**, is established in the annual performance evaluation, with quantitative scoring across four dimensions: environmental certification, resource consumption, pollutant emissions, and green innovation. Suppliers with excellent evaluations receive priority in orders and payment terms, while those failing to meet standards for to consecutive years face quota reductions or elimination.

Promoting quantitative management of environmental performance. The Small Molecules (TCM) Business Division develops the Detailed Rules for Supplier Environmental Performance Evaluation, specifying quantitative targets such as a carbon emission intensity **≤50 kgCO e/RMB 10,000** of revenue and a renewable energy usage rate **≥20%**. In 2025, specialized rectification was completed for 20 key suppliers, continuously improving the overall environmental performance of the supply chain.

	Raw material suppliers	Excipient suppliers	Inner packaging material supplier	Outer packaging material supplier
Production license	124	127	43	40
GMP compliance	77	65	25	/
Environmental permit	71	90	50	32
Health and safety clearance	57	76	46	28
Green factory	28	33	13	11

Building green supply chain

Practicing green transportation

The Global Business Division continues to advance the construction of a green logistics system, focusing on both load optimization and route planning to effectively achieve energy conservation and emission reduction in transportation. In the loading process, through wave management, intelligent order consolidation, and the “single-line multi-delivery” model, we have significantly improved vehicle loading rates and reduced empty-load rates, resulting in a **20%** year-on-year decrease in transportation energy consumption. In route planning, leveraging the TMS transportation management system, we integrate multi-dimensional information such as real-time traffic conditions, order density, vehicle load, and delivery time windows to achieve intelligent and dynamic route optimization. This has led to a **20%** reduction in both annual mileage and fuel consumption, along with a notable improvement in vehicle turnover efficiency.

Enhancing green warehousing

In 2025, to support business development, Yifan Pharmaceutical added approximately **7,000** square meters of warehouse space and introduced a “distributed cold source central air conditioning system + IoT integrated management system”. This solution ensures GSP-compliant storage while saving over **10%** in initial investment, reducing operational energy consumption by over **20%**, and improving comprehensive energy utilization efficiency by over **20%**. Through dual temperature and humidity control and intelligent management, the system achieves precise environmental regulation and remote operation and maintenance, effectively ensuring drug storage safety and reducing management burdens.



New Warehouse Space Intelligent Warehousing System of Yifan Pharmaceutical



Intelligent Temperature and Humidity Monitoring System

Implementation of localized procurement

To enhance supply chain resilience and achieve cost reduction and efficiency improvement, the Procurement Management Center of the Small Molecules (TCM) Business Division has vigorously promoted the localized procurement of raw materials. The specific measures and outcomes are as follows:

Developing a regional resource map to identify key procurement areas

Supplier resources in the locations of various subsidiary companies were reviewed, determining Bozhou as a key procurement base for TCM medicinal slices. Simultaneously, potential supplier databases in Sichuan, Hebei, and other regions were identified, laying the foundation for localized procurement.

Implementing the "Direct Sourcing from Origin" model to reduce intermediate links

For key authentic medicinal materials such as honeysuckle and wild chrysanthemum, the Company bypasses intermediaries and directly conducts bidding procurement from standardized planting bases or processing enterprises in Hubei, Tianchang, and other regions, effectively reducing procurement costs.

Cultivating local potential suppliers for win-win cooperation

Provide technical guidance to local suppliers with development potential, helping them meet procurement standards. This ensures stable supply while reducing procurement costs.

Significant increase in bidding procurement ratio with cost reduction and efficiency improvement

The proportion of bidding procurement for TCM prepared slices reached 80% in 2025, a **50%** increase compared to 2024. This has significantly shortened the procurement cycle and effectively controlled costs.

Promoting centralized procurement of excipients to gain price advantages

The Company signed long-term agreements with strategic suppliers, achieving a **30%** price reduction for coating powders. This enhances economies of scale and bargaining power in excipient procurement.

Reviewing single-supplier materials and implementing dual/multi-source strategies

The Company conducted a thorough review of key materials and promoted the transition from single suppliers to dual or multi-source suppliers, reducing the risk of supply disruptions.

Integrating internal demand resources to leverage scale procurement advantages

The Company consolidated procurement demands from subsidiaries across business divisions to form bulk purchasing power, securing more favorable prices in supplier negotiations.

Introducing new suppliers to strengthen competition mechanism

The Company stimulated competition by introducing new suppliers. For example, after introducing new composite film suppliers, the overall price of composite films decreased by 5%; after introducing a new carton supplier, prices dropped by 2%.

3. Deepening industry collaboration

Strengthening industry-academia-research collaboration

Yifan Pharmaceutical adheres to a patient-centric and clinically value-driven philosophy of responsible innovation, serving as the core engine for driving long-term social and environmental value. By fostering an open collaborative ecosystem integrating industry, academia, and research, continuously increasing investment in independent R&D, and promoting innovation across the entire product lifecycle, we are committed to developing more effective, accessible, and environmentally friendly pharmaceutical solutions, contributing to global health and sustainable development goals.

The Company accelerates the transformation of innovative achievements through deep integration of "industry-academia-research-application".It engages in in-depth collaborations with universities such as Zhejiang University, Beijing University of Chinese Medicine, and China Pharmaceutical University to bridge basic research and industrial applications..

Strengthening strategic collaborations

In 2025, Yifan Pharmaceutical continued to deepen global industry collaboration, enriching its product portfolio and expanding its market presence through multiple strategic partnerships.

- Secured exclusive marketing rights in mainland China for Bayer's flagship targeted therapies, Stivarga® and Nexavar®;
- Secured exclusive marketing rights in mainland China for the Tecfidera™ from Biogen;
- Secured marketing rights in Colombia and Central America for the licensed product Nilotinib Capsules;
- Secured marketing rights in Mexico and Central America for the licensed product Abiraterone Tablets;
- Secured marketing rights in the Philippines for the licensed product Dydrogesterone Tablets;
- It signed an agreement with Sygardis Rus, LLC for the co-development of oxytocin nasal spray, laying a solid market and resource foundation for future product expansion into Russia and surrounding markets.

In November 2025, Yifan Pharmaceutical Was Invited to Participate in the 91st National Pharmaceutical Fair in Nanjing.



In June 2025, Yifan Pharmaceutical Participated in the BIO International Convention in the United States



In November 2025, Yifan Pharmaceutical Attended the European Congress on Biotechnology.

Case: Yifan Pharmaceutical made its debut at the China Health Ecology Organization (CPEO), collaborating with the industry to build a new ecosystem for pharmaceutical retail growth.

On August 16, 2025, the 18th China Health Ecology Organization (CPEO), themed "Rapid Transformation, Navigating the New Cycle—Reconstructing Growth Momentum and Evolving the Industrial Ecosystem", was held in Bo'ao, Hainan. The conference focused on the development direction of the health industry against the backdrop of pressure across the entire pharmaceutical terminal market. Yifan Pharmaceutical, as a company deeply rooted in the hospital market, made its debut as a new participant in the retail channel. Guided by the core philosophy of "Co-building Golden Categories, Achieving Win-Win with Diverse Categories", it presented systematic solutions to help the retail channel overcome challenges and enhance efficiency.

Moving forward, the Company will continue to refine its product matrix and deepen collaboration models, evolving from a "new face" in the retail channel to a trusted "Category Growth Partner".

The 18th China Health Ecology Organization (CPEO)

(II) Protecting customer rights

1. Responsible marketing

The Company strictly complies with the requirements of laws and regulations such as the *Advertising Law of the People's Republic of China* and the *Drug Administration Law of the People's Republic of China*, adhering to the principles of truthfulness, legality, and integrity in advertising content. We firmly reject false or misleading promotions and take full responsibility for consumer safety. In September 2025, together with 15 pharmaceutical companies, we launched the "Responsible Marketing · Safeguarding Medication Safety" industry initiative. This initiative commits to strict adherence to advertising laws and pharmaceutical marketing standards, eliminating exaggerated claims and misleading consumer practices, and collectively building an integrity-driven marketing system within the industry. The initiative has received full recognition from relevant departments of the National Medical Products Administration, highlighting the commitment of the Company and industry partners to compliant marketing and safeguarding public health.

Expanding marketing training

In April 2025, the Company conducted specialized training for over 1,200 employees in the global marketing and sales departments, inviting industry experts and senior lawyers to provide in-depth interpretations of regulations such as the *Measures for the Record Management of Pharmaceutical Representatives* and the *Advertising Law of the People's Republic of China*. Through case studies and scenario-based simulations, the training systematically explained the hazards and prevention measures for violations such as exaggerated promotions and commercial bribery, effectively strengthening employees' compliance awareness and ideological defense. All participants passed the post-training assessment with a 100% pass rate, laying a solid foundation for standardizing marketing practices and mitigating compliance risks.

In August 2025, tailored training sessions were organized for overseas regional marketing teams, focusing on marketing compliance requirements and cultural differences in various countries. Case studies on localized marketing strategies for products such as Clofarabine and Vincristine were shared to guide teams in adhering to local regulations and respecting cultural diversity. A total of six sessions were held, involving over 800 participants, and 46 feedback suggestions for optimization were collected from the teams.

The Company Organizes Employee Participation in Responsible Marketing Training

Case: Yifan Pharmaceutical held 2025 annual management conference

In August 2025, Yifan Pharmaceutical held its annual management conference under the theme "Integrating Training and Execution: Focusing on Growth". Centered on the core philosophy of "management serving business operations", the event focused on enhancing the practical capabilities of the marketing system to fully empower business growth. In response to the evolving pharmaceutical industry policies and intensifying market competition, the conference reviewed the business performance of the first half of the year and summarized terminal breakthrough strategies tailored to regional characteristics, injecting strong momentum for market breakthroughs in the second half year. The conference adhered to the principle of "using training to promote execution and using execution to validate training", fostering consensus on development through intellectual exchanges and honing core competencies through practical simulations. This laid a solid foundation for the company to seize market opportunities and achieve sustainable growth amid industry transformations.

2025 Annual Management Conference of Yifan Pharmaceutical

Strengthening brand building

In terms of brand building, the Company actively participated in national and provincial-level large-scale academic conferences, leveraging high-level academic promotion platforms to significantly enhance the brand exposure and industry influence of its core products. At the same time, closely aligning with the actual characteristics of various regional markets, the Company developed differentiated marketing strategies, moving away from a “one-size-fits-all” approach to ensure more precise and effective brand communication.

In 2025, Yifan Pharmaceutical continued to enhance its global brand influence through a dual approach of offline deep engagement and online content dissemination.

Yifan Pharmaceutical Participated in Industry Academic Annual Meetings and Specialized Academic Conferences

In July, the Company showcased at the Singapore Global Innovative Medicine Forum, setting up a dedicated booth to display its core products in hematologic tumors and solid tumors, as well as its sustainability achievements. It also hosted a sub-forum titled “Innovative Drug R&D and Global Accessibility”, attracting over 300 companies for collaboration discussions. The event received coverage from overseas media more than 20 times, further expanding the Company’s international business cooperation network.



In September, the Company participated in the Chinese Society of Hematology Annual Meeting organized by the Chinese Medical Association, where it showcased its hematology products, including Compound Huangdai Tablets, Pufanle, Clofarabine, and Vincristine, and received over 500 on-site inquiries.

2.Customer communication services

We always prioritize customer needs, building a professional, transparent, and efficient multi-channel customer service system as a key pathway to drive sustainable corporate development. We actively uphold the United Nations Sustainable Development Goals of “Good Health and Well-being” and “Responsible Consumption and Production”. The Company continuously refines marketing standards, enhances service professionalism, and optimizes the omnichannel interaction experience. This not only provides customers with safe, professional, and thoughtful all-around support but also empowers the steady improvement of public health through innovative practices. We are committed to setting a benchmark for societal health development, ensuring that health and well-being benefit a broader population.

In 2025, the Company continued to optimize its “three-level complaint handling mechanism”, establishing an integrated online and offline complaint channel (400 hotline, official App, WeChat official account, and offline service outlets). It defined six categories of complaint classification standards (product quality, service attitude, usage consultation, etc.), established tiered response time frames (24 hours for general complaints, 2 hours for major complaints), and introduced a customer satisfaction callback mechanism. Through monthly case reviews, the “Complaint Handling Optimization White Paper” was produced. Throughout the year, 8 processes were optimized, and a dedicated response channel for pediatric medication consultation was added, continuously enhancing the customer service experience.

Proportion of complaint types



Complaint handling

2025Total complaints: **467** Complaint resolution rate:**100%** Average handling time:**2.8 days** Compared to 2024:Decreased by **35%** Customer satisfaction rate: **95.2%** Compared to 2024: Increased by **5.9%**

In 2025, the Company's customer service system continued to improve in quality and efficiency. The 400 service hotline received a total of 4,628 calls throughout the year, with a stable monthly service volume of approximately 400 calls and a daily response capacity of 20–30 calls, ensuring "zero busy signals and zero missed calls" for customer inquiries. Building on this, the Company proactively conducted 1,388 customer callbacks, covering 30% of the total incoming calls, driving the service model to upgrade from "passive response" to "active care", further strengthening the foundation of customer trust.

The Global Business Division corporate email received 1,454 valid emails throughout the year, 98% of which were in English, reflecting the breadth and depth of the Company's global presence. All email handling strictly adhered to the *Data Security and Privacy Protection Policy*, fully aligning with the ISO 27001 Information Security Management System. This ensured end-to-end encryption of customer business information, access logging, and regular audits, establishing a robust data security defense in line with international standards.

Service creates value

In 2025, by continuously optimizing our service system and deepening global collaboration, we created more value for our domestic and international partners.

In terms of full product life cycle services, the Company has closely collaborated with domestic and international partners to accelerate key regulatory upgrades: In China, it successfully supported the National Medical Products Administration (NMPA) in approving the supplemental application for changing the administration of Ryzneuta® from 48 hours to 24 hours, providing an official basis for earlier clinical medication and helping to enhance patient treatment outcomes and medical efficiency; in the European Union, it facilitated the approval of the self-injection indication for Ryzneuta®, making home-based treatment possible and significantly improving patient accessibility and convenience.

(III) Supporting public welfare initiatives

Yifan Pharmaceutical actively fulfills its corporate social responsibility by deeply engaging in public welfare initiatives. Leveraging its professional expertise in the pharmaceutical and healthcare sectors, the Company proactively participates in social services, precisely addressing grassroots needs. Through health assistance, industrial support, and various other forms of aid, Yifan Pharmaceutical continuously empowers community development and improves people's livelihoods. While boosting local economic growth, we are committed to promoting social progress, demonstrating the responsibility and accountability of a pharmaceutical enterprise in the new era.

In 2025, the Company stood out for its remarkable performance in corporate social responsibility and philanthropy, and was selected as one of the "Hangzhou 2025 Listed Company with Growing ESG Strategic Philanthropic Influence". It also received prestigious philanthropic honors, including being named one of the "Top 500 Chinese Manufacturing Enterprises in Philanthropy" and one of the "Top 500 Chinese Private Enterprises in Philanthropy".

Community Summer Cooling Services

Employees Promote Anti-Fraud Awareness Among Local Businesses

Annual Five-Water Governance Initiative

Organizing "5e Convenience Services" to Provide Free Appliance Repairs for Residents

Volunteering at Traditional Chinese Medicine Hospitals for Residents

Organizing Employee for Voluntary Blood Donation

2025

Total investment in public welfare activities:RMB **6.0176** million

Case: Yifan Pharmaceutical organizes the "Jianxin Health Care" brand public welfare activity

From January to December 2025, Yifan Pharmaceutical carried out activities across 15 provinces and cities in China, organizing teams of medical experts to conduct free clinics, promote hematological tumor awareness, and provide charitable drug donations in remote areas and communities. The activities were broadcast live on multiple platforms, thereby enhancing the brand's social reputation.

"Jianxin Health Care" Brand Public Welfare Activity

04

SAFEGUARDING EMPLOYEE DEVELOPMENT WITH PEOPLE-ORIENTED APPROACHES

Contributing to Sustainable Development Goals (SDGs)

Governance

The Company has established an employee development governance system centered around the Human Resources and Administration Center, with collaborative promotion from various business units. This system centrally formulates overarching policies in areas such as employee relations, compensation and benefits, talent development, and occupational health and safety, ensuring unified implementation standards across all business units. Under the Board of Directors, the Remuneration and Assessment Committee is responsible for reviewing compensation incentive plans and overseeing the implementation of performance assessments for directors and senior management. In occupational health and safety, a three-tier management mechanism has been established, led by the EHS Committee and implemented by dedicated departments at each base, ensuring comprehensive safeguarding of employee rights and interests.

Strategy

The company adheres to the philosophy of “Talent as the Foundation, Value Co-creation”, with the core objective of “Empowering Employee Growth and Fostering Talent Development”. It has established a systematic talent cultivation and incentive mechanism. In terms of rights protection, the Company fully implements equal employment and refines the compensation and benefits system. For talent development, it continuously enhances talent density and tiered talent reserves through tiered and categorized training, dual-track promotion, and key talent programs. In occupational health and safety, the Company strictly complies with regulations and international standards, strengthening risk identification, emergency drills, and safety training. Regarding employee well-being, it deepens employee care and democratic management, fostering a warm, inclusive, and equally participatory work environment, thereby tangibly enhancing employees’ sense of gain, happiness, and belonging.

Risks and opportunities

Category	Specific content	Countermeasure
Talent loss risk	Under the situation of intense market competition for core R&D and international talents, inadequate incentive mechanisms and blocked career development pathways may lead to the loss of key personnel, affecting business continuity and innovation capabilities.	Continuously optimize the compensation and incentive system, improve the dual-track career advancement mechanism of “management + professional expertise”; promote long-term incentives such as equity incentives and project profit-sharing to strengthen the alignment of interests with core talent; enhance corporate culture identification and boost employees’ sense of belonging.
Employment compliance risk	Inadequate implementation of employment policies, non-standard labor contract management, and improper application of working hour systems may lead to labor disputes or regulatory penalties, affecting corporate reputation and operational stability.	Strictly comply with labor laws and regulations, standardize labor contract signing and employment management; conduct regular self-inspections on employment compliance and promptly rectify identified issues; strengthen legal and regulatory training for the HR team to enhance compliance awareness and execution capabilities.
Occupational health and safety risk	Inadequate control of occupational hazards, insufficient safety training, and lack of emergency drills during production processes may lead to occupational health damage or safety incidents, endangering employees’ lives and health as well as normal business operations.	Enhance the occupational health and safety management system, strengthen hazard monitoring and protection; conduct regular safety training and emergency drills to improve employees’ safety awareness and emergency response capabilities; increase safety investment to ensure the provision of protective facilities and equipment.
Talent development opportunity	A systematic talent development system can enhance employees’ professional skills and overall competencies, stimulate organizational vitality, and provide solid talent support for sustained business growth.	Refine the tiered and categorized training system, advance key talent programs such as the “Voyager Program”; deepen industry-education integration, strengthen collaboration with universities and research institutions; build an internal instructor database and course resource library to foster a continuous learning culture.

Objectives and targets

Labor contract signing rate: **100%** | Social insurance coverage rate: **100%** | Total number of employees: **4,182** | Number of occupational health and safety training sessions: **60** | Number of participants in occupational health and safety training: **2,687** persons

(I) Safeguarding employee rights and interests

1. Employment, compensation and benefits

Protection of employee rights and interests

Yifan Pharmaceutical strictly adheres to laws and regulations such as the Labor *Law of the People’s Republic of China and the Labor Contract Law of the People’s Republic of China*. The Company signs labor contracts with all employees in accordance with the law, upholds the principles of fairness, justice, and transparency in recruitment management, and continuously promotes the standardization and normalization of employment practices to build harmonious and stable labor relations. In line with the *Employee Relationship Management System* and the *Recruitment* and *Employment Management* System, the Company has further strengthened its onboarding review mechanism by implementing stricter verification procedures to prevent the inadvertent employment of individuals under the age of 16, thereby eliminating child labor at the source. In terms of protecting employee rights, the company fully implements the principle of equal employment, maintains a balanced gender ratio and a diverse age structure, and has not encountered any labor dispute cases involving child labor or forced labor. Additionally, all labor contracts include specific clauses regarding labor protection, working conditions, and occupational hazard prevention, effectively safeguarding the legitimate rights and interests of employees.

In 2025, all subsidiaries of the Company achieved a 100% labor contract signing rate and 100% social insurance coverage rate.

Gender structure



Male employees **2,398** persons

Female employees **1,784** persons

Education structure



Proportion of employees with Master's Degree or Higher **6.79%**

Proportion of employees with Bachelor's Degree **35.87%**

Proportion of employees with Associate Degree or below **57.34%**

Age structure



Under 30 years old **1,010** persons

30-50 years old **2,548** persons

50 years old and above **624** persons

Work type structure



Percentage of production staff **38.55%**

Percentage of financial staff **3.90%**

Percentage of sales staff **23.91%**

Percentage of administrative staff **2.30%**

Percentage of technical staff **19.99%**

Percentage of managerial staff **11.35%**

Compensation and benefits

The Company has established a diversified compensation and benefits system centered on equal pay for equal work, balancing fairness and incentives.

In terms of compensation, various models such as position-based wages, position-skill-based wages, and "base salary + piece-rate/commission/performance" are implemented according to the characteristics of different roles. By signing special collective wage agreements and establishing a compensation incentive mechanism that grows in tandem with the Company's performance, the Company ensures continuous improvement in employee compensation. In 2025, the Company's business divisions revised and issued the *Performance Management System for Marketing Employees and the Job Qualification Management System*, further refining the performance management and competency assessment mechanisms, thereby providing solid institutional support for differentiated compensation and employee career development.

In terms of welfare benefits, the Company has progressively improved its "basic benefits + personalized benefits" system. Paid annual leave, marriage leave, bereavement leave, maternity leave, and breastfeeding leave are provided in accordance with the law, fully safeguarding employees' rights to rest and leave. At the same time, the Company continues to enrich its unique corporate benefits. In September 2025, the Company's business divisions issued the Welfare Management System, specifying benefits such as holiday gifts for Spring Festival, Dragon Boat Festival, Children's Day, and Mid-Autumn Festival, as well as birthday blessings for employees. Combined with holiday bonuses, wedding and childbirth gifts, condolence payments, and various work-related subsidies, these measures effectively enhance employees' sense of fulfillment and belonging.

2.Achieving talent development

In 2025, closely aligning with the "Innovation and Internationalization" strategy and focusing on "Organization, Talent, and Culture" as core drivers, we advanced the transformation of the HR and administration functions from traditional support to a dual-wheel drive of "empowerment + risk control". This effort continuously strengthened organizational capabilities and operational systems, laying a resilient foundation for business growth. During the reporting period, employee training investment reached RMB 3.825 million. Through a diversified training system, layered management, and customized development mechanisms, we systematically promoted end-to-end talent management from "selection" to "development", striving to enhance talent density and tiered talent reserves, and efficiently translating talent value into the core driving force for organizational evolution.

Strengthening the foundation for talent growth

For different groups such as new employees, incumbent staff, core talents, and management personnel, we developed differentiated training plans covering key areas including job skills, professional quality, sustainable development concepts, and compliance knowledge, ensuring precise alignment between training provision and job requirements. In 2025, the completion rate for core job skills training reached 100%, new employee onboarding training achieved full coverage, and employee training satisfaction reached 92%, reflecting continuous improvement in the effectiveness of the training system and employee recognition.

Training groups	Training courses	Training content	
New employees	“Strategic Navigation, Cultural Integration” onboarding training	The Company innovatively designed a dual-module training program combining “**Strategic Orientation + Cultural Internalization**”. By interpreting China’s opportunities in the wave of innovative drug development, new employees are guided to align their roles with the Company’s strategic direction. A “Cultural Storytelling Session” is organized, where senior leaders share practical cases of practicing the “Global Collaboration” culture during compliance challenges in Europe and the United States. In 2025, the onboarding training coverage rate for new employees reached 100%.	
Middle level and frontline employees	“Voyager Program”	In accordance with the *Employee Career Development Management Measures*, the Company has established a dual-track promotion system comprising “Management Sequence + Professional Sequence”, providing employees with clear career development paths. In 2025, the “Voyager Program” focused on middle level and frontline employees, centering on the core competencies of “**self-management, team management, and project management**”. Through methods such as classroom instruction, case studies, and practical exercises, the program established a special fund and engaged high-quality instructors to ensure its effective implementation. In 2025, 25% of employees who received promotions underwent job adjustments, and the retention rate of key talent reached 96%, effectively mitigating the risk of core talent loss and supporting business growth.	
R&D, production, and commercial director level and above employees	Special training program for innovation and internationalization	To support international development, the Company has introduced a “External Expert Guidance + Internal Workshops” training model for triple-role personnel. We invited experts from international regulatory agencies and leading enterprises to interpret EU and US market access regulations, AI-driven drug R&D, and other cutting-edge trends, directly addressing strategic pain points. Participants developed a *Three-Year Strategic Plan Draft*, which was reviewed by the senior management team and incorporated into annual objectives, ensuring effective translation of strategic insights into operational implementation.	

Case: Innovative cultural training model deepens employees’ value recognition

The company introduced an innovative cultural training format using a “murder mystery script game” approach, breaking away from traditional team-building models. Through small-team trials and rapid iterations, employees engaged in immersive experiences, solving puzzles layer by layer and deciphering cultural codes, thereby deepening their understanding and identification with the corporate culture. The activity was conducted 4 times in a year, covering nearly 200 core key personnel, significantly enhancing the engagement and effectiveness of cultural dissemination.

Innovative Team-building Activities

Establishing a skills training platform

In 2025, we continued to carry out the “Hundreds, Thousands, and Tens of Thousands” employee labor competition, actively building a multi-position, multi-level skills training system. The competition content was closely aligned with practical production, covering areas such as the Environmental Safety Department’s fire safety competition, the Equipment Department’s electromechanical and instrumentation skills competition, the Technical Center and Quality Management Department’s inspection and testing skills contest, and the production department’s forklift operator skills competition. These initiatives provided employees with a practical platform for skill demonstration and exchange. By promoting learning through competition and using competitions as training, we not only effectively enhanced employees’ professional technical capabilities and job competence but also strengthened cross-departmental collaboration awareness and team cohesion. This fostered a positive atmosphere of “competing, learning, striving, and advancing together”, achieving remarkable results in talent development and work performance.

Forklift Skills Competition

Advancing the performance appraisal system

To strengthen the strategic orientation of performance management, the Company has deeply integrated key sustainability indicators (such as workplace safety, teamwork, and participation in energy-saving and emission-reduction initiatives) into the employee performance appraisal system. The appraisal results are directly linked to salary adjustments and promotion pathways, fully leveraging the guiding role of performance management. At the same time, the Company continues to optimize long-term incentive mechanisms, offering core talent diversified incentives such as equity incentives and project profit-sharing. This further aligns employee interests with those of the Company, fostering a career community framework featuring “shared responsibility, co-created value, and shared benefits”, effectively stimulating the internal drive and talent creativity in the Company.

(II) Safeguarding employee health

1.Occupational health and safety

The Company strictly adheres to the *Occupational Disease Prevention* and *Control Law of the People’s Republic of China*, the *Work Safety Law of the People’s Republic of China*, and international occupational health and safety management standards, always prioritizing employee health and safety. By establishing a comprehensive occupational health and safety management system, the Company systematically conducts risk identification, emergency drills, and safety training, effectively controlling safety risks during project construction and operation, and ensuring the physical and mental well-being of employees and production safety.

Medical examination coverage of employees: **100%**

Number of occupational health training sessions: **60** sessions

Number of participants in occupational health training: **2,687** persons

Organizing occupational health and safety training

In response to the Shenzhen Stock Exchange’s guidelines on strengthening occupational health and safety responsibilities, the Company organized specialized sustainability training using a combined training and practice model. We invited experts from the Ministry of Emergency Management and occupational health specialists from the Chinese Center for Disease Control and Prevention, who provided in-depth analyses of *Emergency Response Standards Under the ESG Framework* and *Occupational Health Risks* and *ESG Compliance in the Pharmaceutical Industry*. Following the training, all employees signed the *ESG Health and Safety Commitment*, integrating health and safety principles into daily operations. As a result of the specialized training, the average emergency response time was reduced by 30%, and the occupational health risk identification rate increased to 85%, achieving dual improvements in awareness and capability.

Strengthening occupational health and safety management

The Company fully implemented its primary responsibility for occupational health and safety. Each business division, in line with its operational characteristics, systematically advanced the development of occupational health and safety management systems, continuously enhanced risk prevention and control capabilities, and effectively safeguarded employees’ physical and mental health.

<table>
<tr><td>Small Molecules (TCM) Business Division</td><td colspan="3">

Annually commission occupational health institutions to test hazardous positions, ensuring employees' right to know; establish a complete testing archive, covering commissioning agreements, sampling records, reports, and corrective plans, ensuring full traceability and compliant management.
Commission professional institutions to conduct full-cycle occupational health examinations from "pre-employment, during-employment, to post-employment": screening for occupational contraindications before employment, executing specialized examinations based on risk levels during employment, and clarifying health status to define responsibilities after demission. Establish "one file per person" health records, promptly reassign employees with contraindications from hazardous environments.
Provide personal protective equipment (PPE) compliant with national standards based on job hazard characteristics, implementing a system of "on-demand allocation, dedicated management, and regular replacement". Strengthen PPE usage training and on-site supervision to ensure correct wearing and timely replacement, guaranteeing effective protection.
Standardize the setup of occupational health warning signs compliant with GBZ 158 standards in workplaces; develop standard operating procedures (SOPs) for each position, specifying requirements for operations such as chemical reagent handling, forbidding eating or smoking, etc., and enhance on-site supervision and inspection to prevent violations.

In 2025, the physical examination coverage rate reached 100%, with over 360 employee occupational health records established. A total of 130 safety training sessions were conducted. The provision rate of safety protection equipment for key positions reached 100%, and the annual work-related injury incidence rate was significantly lower than the industry average. No major occupational health and safety accidents occurred.

 

Occupational Health Warnings Set in the Company</td></tr>
<tr><td rowspan="2">Biologics Business Division</td><td>Hefei Plant</td><td>Gradually advance the Occupational Health and Safety Management System and the "Three Simultaneities" in occupational health, confirming the service unit for occupational health control effectiveness evaluation, and mitigating occupational health risks from the source.</td><td>Occupational Health and Safety Emergency Drills
 
  </td></tr>
<tr><td>Beijing Plan</td><td colspan="2">Regularly conduct testing of occupational hazard factors, risk assessments for positions exposed to hazards, and suitability evaluations of personal protective equipment. Dynamically monitor the health status of employees in exposed positions and organized refresher occupational health education for all staff to strengthen regulatory awareness and protective capabilities. In 2025, a total of 91 on-the-job occupational health examinations, 15 pre-employment health examinations, and 5 post-employment health examinations were conducted, achieving full-cycle health surveillance for employees in hazard-exposed positions.</td></tr>
<tr><td>Synthetic Biologics Business Division</td><td colspan="2">All subsidiaries under the Synthetic Biologics Business Division have fully obtained ISO 45001 Occupational Health and Safety Management System certification. Through activities such as hazard identification, hands-on training with emergency equipment, and team safety culture initiatives, employee safety awareness and emergency response capabilities have been continuously enhanced. In 2025, the Division allocated RMB 5.9939 million for labor protection supplies and welfare expenses, an increase of RMB 1.6014 million compared to the previous year. Additionally, RMB 460,100 was spent on health examinations, providing solid financial support for occupational health and safety management.</td><td>Anqing Xinfu Organizes Occupational Health and Safety Emergency Drills
 
  </td></tr>
</table>

(III) Enhancing employee well-being

1.Caring for employees' life

The Company actively promotes work-life balance by organizing special care activities such as birthday greetings and holiday benefits, enriching employees' leisure time and strengthening team cohesion. Meanwhile, through continuous care initiatives in various forms, from physical and mental health to career development, the Company fosters a warm and inclusive work environment, helping employees achieve better balance and growth in both their career and personal lives.

Practicing employee care

The Company always adheres to a people-centered approach, integrating care into daily routines to genuinely enhance employees' sense of fulfillment, happiness, and security. On important occasions such as the Dragon Boat Festival, Mid-Autumn Festival, and employee birthdays, the Company meticulously prepares exclusive holiday gift packages to convey organizational warmth. Throughout the year, birthday cake vouchers were distributed more than 4,000 person-times, ensuring that blessings arrive as promised. To strengthen health protection, Hangzhou Xinfu has continuously enrolled employees in the "On-the-Job Employee Medical Mutual Assistance Program" for many years and applied for hospitalization allowances for 29 employees, effectively alleviating their medical burdens. Additionally, the Company consistently addresses the needs of employees' families. In August, the "Spring Breeze Scholarship" activity was launched, distributing scholarships totaling RMB 12,900 to employees' children to support their dreams. At the same time, the Company enriches employees' leisure time through engaging activities and holds warm farewell ceremonies for retiring colleagues, paying tribute to their dedication. These efforts ensure that every employee feels the warmth of the extended family throughout their career journey.

Employee "Watermelon Eating Contest"



Themed Exchange Activities for Young Employees

"Spring Breeze Scholarship" Program

Special Care Activities for Retired Employees

Employee Cultural and Sports Activities

Addressing Difficulties for Employees

The Company's labor union places great emphasis on caring for employees in need, establishing and improving a comprehensive filing system for employees facing difficulties to ensure targeted and effective support. In 2025, the Company's labor union distributed over RMB 400,000 in condolence payments and extended support to more than 500 employees; the labor union of Hangzhou Xinfu conducted a total of 75 instances of various forms of care, distributing caring fund totaling RMB 59,380. These efforts covered multiple aspects, including congratulations on marriages, care for new parents, hospital visits, and bereavement support. Specifically, the union extended marriage congratulations to 4 couples, offered childbirth care to 8 couples, visited 44 employees hospitalized due to illness, and expressed condolences to 19 individuals, ensuring timely delivery of the Company's warmth and care. Additionally, the union actively coordinated with higher-level labor unions to complete the application and review process for 3 employees in need, further expanding support channels and effectively alleviating difficulties faced by employees.

Caring for female employees

In terms of protecting the rights and interests of female employees, the Company adheres to the principles of equal guaranteeing and humanistic care, diligently safeguarding their legitimate rights. We strictly implement fair mechanisms regarding compensation, promotion, and career development to ensure equal opportunities for both male and female employees. For pregnant and nursing employees, the Company makes reasonable adjustments to job positions and work arrangements, establishes standardized nursing rooms in work areas, and enhances supportive and convenient facilities. Hefei Yifan Biopharmaceutical has established a municipal Class II mother-and-baby room, which is fully equipped with comprehensive functions. It adopts paperless management, and offers a convenient process, serving numerous breastfeeding women within the Company. Furthermore, Hangzhou Xinfu provides female employees with "medical security for special diseases of female employees". The aforementioned measures provide all-round protection for their physical and mental health as well as their professional development.

2. Strengthening democratic management

The Company values employee feedback and continuously improves consultation mechanisms and communication channels to effectively safeguard employees' rights to information, participation, expression, and oversight. Under the leadership of the Company's Party committee and with strong support from the administration and the higher-level trade union, employees' legitimate rights and interests are earnestly protected. The trade union has established a Labor Law Supervision Committee, a Labor Dispute Mediation Committee, and a Wage Collective Consultation Agreement Monitoring Group, all approved by the higher-level trade union and operating in full compliance.

To strengthen democratic management, the trade union has set up department/workshop-based WeChat groups for the collection of employees' opinions and suggestions online, and established an offline "Emotional Service Station" for in-person communication. By integrating "online and offline" efforts, the Company continuously expands democratic participation pathways and advances practical democratic management.

Yifan Pharmaceutical's "Emotional Service Station" for Employees

05

GREEN OPERATIONS TO PROTECT OUR COMMON HOME

Contributing to Sustainable Development Goals (SDGs)

Governance

Yifan Pharmaceutical has consistently integrated green development and low-carbon transformation into its corporate governance and strategic core. The Company operates a three-tier environmental management system with decision-making by the Board of Directors, coordination by the management, and implementation at the operational level, focusing on compliance, clean production, resource conservation, and green technology as key drivers to comprehensively advance environmental governance and support high-quality and sustainable development.

Strategy

Guided by the principles of green transformation, clean production, resource conservation, and environmental friendliness, and driven by both technological innovation and green manufacturing, the Company is building a safe, low-carbon pharmaceutical and bio-manufacturing industrial system. The Company promotes clean production and process upgrades, increases investment in green technology R&D, and implements green procurement to strive to become an environmentally friendly enterprise. By deeply integrating ecological and environmental concepts into all aspects of its development, the Company sets a benchmark for green transformation in the industry.

Risks and opportunities

Category	Specific content	Countermeasure
Policy compliance risk	National and local environmental regulations are continuously tightening. For example, the *Opinions on Optimizing Environmental Impact Assessment for the Pharmaceutical Industry* imposes stricter requirements on EIA management and pollutant control for pharmaceutical projects. Emerging controls on new pollutants and adjustments to pollutant discharge permits may increase compliance costs. Failure to adapt in time could lead to penalties for non-compliance.	Establish a dynamic tracking mechanism for environmental policies and assign personnel to interpret the latest regulations and industry standards. Continuously improve management systems, optimize the permit application and adjustment processes, ensure all production and operation activities comply with policy requirements, and proactively cooperate with regulatory spot checks and routine monitoring.
Pollution control risk	In the production of pharmaceuticals and APIs, the treatment of wastewater, waste gas, and hazardous solid waste (e.g., antibiotic residue) is challenging. Improper monitoring or disposal may lead to excessive emissions, leaks, and other issues, resulting in environmental accidents and reputational damage.	Strengthen the application of the online environmental monitoring system (EMS) to achieve intelligent, end-to-end monitoring of pollutant discharge. Strictly follow procedures for the classification, storage, and disposal of solid waste. Entrust qualified professional agencies for compliant disposal of hazardous waste. Continuously increase environmental protection investments and optimize the efficiency of pollution control facilities.
Green transformation risk	The green transformation of traditional production processes requires significant investment and long lead times. R&D in green technologies such as synthetic biology involves uncertainties. Delays in the transformation may result in non-compliance with industry green development requirements and negatively affect market competitiveness.	Plan environmental investments rationally and carry out production process upgrades in phases, prioritizing continuous, automated, and low-temperature processes. Increase investment in green technology R&D, replacing traditional high-pollution chemical synthesis with synthetic biology manufacturing to reduce transformation risks.
Market competition opportunity	As consumers and investors pay greater attention to corporate environmental performance, ESG performance has become a core component of corporate competitiveness. Leading companies' green practices can guide industry development and enhance brand reputation and market recognition.	Improve the ESG governance system, enhance the quality of environmental information disclosure, and build an image as an environmentally friendly enterprise. Integrate green development concepts into brand building, and leverage a compliant and environmentally responsible production system to strengthen trust from customers and investors, thereby enhancing market competitiveness.
Low-carbon development opportunity	With the advancement of the "dual carbon" strategy, carbon reduction is becoming increasingly important for the pharmaceutical industry. Broad opportunities exist in areas such as clean energy substitution and carbon accounting system development, supporting the Company's high-quality, sustainable development.	Optimize the energy mix by increasing the share of clean energy such as natural gas. Establish a robust carbon accounting and environmental monitoring system, plan a clear carbon reduction roadmap, and gradually reduce the carbon footprint. These efforts align with low-carbon development requirements and help the Company seize early opportunities in the industry's green transformation.

Objectives and targets

Total investment in environmental protection: RMB **43.6274 million**

Total greenhouse gas emissions: **109,782.35** tCO_2e

Total water consumption: **543,715.59** tons

Number of environmental pollution accidents: **0**

Number of major administrative penalties due to environmental incidents: **0**

(I) Strengthening environmental management

1. Environmental compliance management

Yifan Pharmaceutical strictly complies with national environmental laws and regulations, including the *Environmental Protection Law of the People's Republic of China*, the *Regulations on the Administration of Pollutant Discharge Permits*, and the *Cleaner Production Promotion Law of the People's Republic of China*. Based on the production characteristics of the pharmaceutical industry, the Company has comprehensively implemented a three-tier environmental compliance management system with "group-level coordination, tiered implementation, and company-wide participation", and established a full-process environmental management system, covering R&D, production, supply chain, and waste disposal.

In 2025, the Company continued to improve its environmental management documentation, clearly defined environmental responsibilities for each role, and incorporated environmental compliance into departmental and employee performance assessments, forming a closed-loop management mechanism featuring "responsibility assigned to each role and accountability linked to each employee". Besides, all manufacturing sites have established environmental management systems, with some sites receiving honors such as "Environmental Protection Integrity Enterprise" and "Green Factory".

Refined pollutant discharge permit management and monitoring

The Company strictly implements the "one-permit" management system for pollutant discharge permits. All manufacturing sites have legally obtained pollutant discharge permits and strictly follow permit requirements to regulate discharge activities. The Small Molecules (TCM) Business Division has established a dual monitoring system combining "online real-time monitoring + offline periodic testing". Online monitoring equipment is installed at key points such as wastewater treatment stations and waste gas outlets, connected to the regulatory platform of local ecological and environmental authorities, enabling real-time data transmission and dynamic tracking of pollutant discharge.

In 2025, the Company conducted various environmental monitoring activities covering wastewater, waste gas, noise, soil, and other indicators. All results met national and local discharge standards, and no excessive emissions occurred.

Yifan Pharmaceutical's Online Monitoring Equipment

Routine risk prevention & control and emergency response

The Company has built a full-chain environmental risk prevention system in the principle of “prevention first, combined with control measures”. It systematically identifies environmental risks, focusing on key areas such as hazardous chemical storage, wastewater treatment, and hazardous waste disposal, and develops and dynamically updates graded control measures. The Company has improved its environmental emergency plan system, including comprehensive emergency plans, specific emergency plans, and on-site response procedures. Regular emergency drills are conducted for scenarios such as hazardous waste leakage, wastewater treatment plant accidents, and waste gas treatment facility failures, significantly enhancing emergency response capabilities. Additionally, an internal mechanism for hazards reporting and rewarding has been established, encouraging employee participation in environmental risk inspections, ensuring early detection and timely resolution of environmental risks.

2. Strengthening pollution prevention and control

Waste treatment: embracing reduction and resource utilization

The Company has established a hazardous waste management system based on “segregated collection – standardized temporary storage – compliant disposal”, ensuring full traceability and oversight. The Small Molecules (TCM) Business Division has set dedicated collection containers and signage at sources of hazardous waste, such as production workshops and R&D labs, with clear classification standards and collection procedures. Standardized hazardous waste storage rooms are equipped with anti-leakage, fireproof, and explosion-proof safety devices and managed under a “double-key, double-person” system. All hazardous waste is handed by the Synthetic Biologics Business Division over to qualified professional agencies under formal contracts, with strict adherence to the hazardous waste transfer manifest system. In 2025, the compliant disposal rate of hazardous waste reached 100%.

The Company promotes a general solid waste management strategy prioritizing “reduction first, resource utilization primarily” to minimize environmental impact. General solid waste from production, such as waste packaging materials, medicinal residues, boiler ash, and sludge, is segregated and recycled: recyclable packaging materials like waste cartons and plastic bottles are collected and reprocessed by the Biologics Business Division; biomass waste such as medicinal residues and sludge is used by the Small Molecules (TCM) Business Division for farmland fertilization or biomass power generation; production scrap is crushed and reused by the Synthetic Biologics Business Division as raw material. Additionally, a household waste sorting and recycling system has been implemented, with sorted waste bins at all sites to encourage employee participation. The harmless treatment rate of household waste reached 100%.

Yifan Pharmaceutical’s Recyclable Packaging Materials

Pollutant treatment: achieving compliance discharge through technology

To address different types of pollutants from pharmaceutical production, including process waste gases, laboratory emissions, and odorous gases, the Company adopts a treatment model of “segregated collection + targeted treatment”. The Biologics Business Division captures process waste gases by collection hoods and treated via activated carbon adsorption, alkaline solution scrubbing, or catalytic combustion to ensure compliance.. In 2025, the Company upgraded its waste gas treatment facilities, adding and retrofitting equipment. Emission concentrations were well below national standards, and total emissions decreased by 14% year-on-year.

The Company has built a full-chain wastewater treatment system covering “source reduction – process control – end-of-pipe treatment” to achieve wastewater reduction and compliance discharge. At the source, process optimization reduces the generation of high-concentration wastewater, such as optimizing product cleaning processes to reduce water use and pollutant discharge. During the process, a segregated wastewater collection system separates high-concentration process wastewater from low-concentration domestic and clean wastewater, improving treatment efficiency. At the end of the process, each manufacturing site is equipped with a standardized wastewater treatment station using mature processes such as “equalization tank + anaerobic + aerobic + advanced treatment”. Treated wastewater is either discharged into municipal sewer systems or reused after advanced treatment. In 2025, the wastewater treatment compliance rate remained 100%.

(II) Improving energy efficiency

1. Efficient energy utilization

Yifan Pharmaceutical adheres to the energy management philosophy of “prioritizing conservation, promoting efficient utilization, and enabling circularity”. Through systematic development, technological innovation, and refined management, the Company continuously improves energy efficiency, reduces energy consumption intensity, and achieves synergy between energy savings and production operations.

Application of high-efficiency energy-saving equipment

The Company has extensively promoted the use of high-efficiency energy-saving equipment to replace traditional energy-intensive equipment. At Hefei XinZhu Site (Biologics), IE4 high-efficiency motors are selected, achieving a **1.5%–3%** efficiency improvement over IE3 motors. High-efficiency chiller plant retrofits have raised the SCOP of conventional chiller plants from 3.0 to over 5.0, significantly improving the energy efficiency of cooling systems. All sites have fully transitioned to LED energy-saving lighting. Utilities equipment such as air conditioners, pumps, and fans have been optimized. A total of **over 200** high-efficiency equipment units have been replaced, increasing equipment energy efficiency by **15%–30%**.



Yifan Pharmaceutical’s High-efficiency Chiller Plant

Production process energy optimization

The Company optimizes process parameters and production workflows based on the characteristics of different products to reduce energy consumption. The Biologics Business Division improved the purified water system by building a concentrate recovery system, enhancing water efficiency while reducing energy use in water production. The Synthetic Biologics Business Division's panthenol process optimization project achieved continuous production, which is stable and economical, delivering significant overall energy savings. The Small Molecules (TCM) Business Division re-insulated steam pipelines in the extraction workshop, replaced all steam traps, and optimized steam pipeline layouts to reduce steam energy losses.

Energy recycling

The Company promotes cascaded energy utilization and recycling to improve overall energy efficiency. The Hefei XinZhu site of the Biologics Business Division recovers condensate water from air conditioners in summer for use in cooling towers, and in winter, recovers steam condensate to preheat fresh air for air handling units, reducing steam and electricity consumption. The Small Molecules (TCM) Business Division recovers industrial steam condensate to boiler water tanks and uses the waste heat from steam condensate to preheat fresh air for air handling units in winter, reducing steam consumption by approximately 200 tons. The Synthetic Biologics Business Division recovers waste heat from production processes for use in related operations, improving overall energy efficiency.

2. Water resource management

The Company selects water-efficient equipment and fixtures, replacing including high-efficiency cleaning equipment and cooling towers to reduce water consumption per unit of product. In terms of process optimization, the Biologics Business Division has improved the purified water preparation process and built a concentrate recovery system, achieving a recovery rate of over **48%**. For water recycling, the Synthetic Biologics Business Division has installed rainwater collection systems, collecting rainwater for landscaping irrigation and floor cleaning. The Small Molecules (TCM) Business Division promotes the recycling of steam condensate, recovering high-temperature condensate from production processes for use in boilers or production cooling. Through these water-saving measures, the Company reduced water consumption by **53%** year-on-year in 2025.

The Company has established a water consumption statistics and analysis system, enabling real-time monitoring and data analysis of water usage across all manufacturing sites and processes to identify potential areas for water savings. Water-saving targets and assessment criteria have been set for each department, linking conservation performance to employee evaluations to encourage company-wide participation. The Company also conducts water conservation awareness and training activities, such as posting water-saving signs and organizing knowledge contests, to strengthen employee awareness and embed water-saving principles into daily practice. Additionally, the Company promotes water conservation among supply chain partners by guiding suppliers to adopt water-efficient production processes, jointly building a water-saving supply chain system.

Yifan Pharmaceutical's Workshop Concentrate Recovery System

3. Developing a circular economy

Yifan Pharmaceutical deeply embraces the principles of the circular economy, centering on "reduction, reuse, and recycling". These principles are integrated into production operations, supply chain management, and the full product lifecycle. Through technological innovation, process optimization, and business model innovation, the Company minimizes resource consumption and waste generation, creating a virtuous cycle of efficient resource utilization and enhanced environmental performance.

Material circulation and reduction: The Company focuses on optimizing material consumption across the entire production process, reducing raw material loss and improving material utilization through process innovation. For the production of product B06, the Biologics Business Division optimized the column chromatography cleaning process by eliminating the use of urea, reducing raw material consumption by 300 kg per batch while cutting 1 ton of high-ammonia-nitrogen wastewater. The Synthetic Biologics Business Division, through fermentation process optimization, increased the fermentation titer and extraction yield of products such as bisabolol and human milk oligosaccharides (HMOs), with the total extraction yield of bisabolol reaching 53.19%, reducing material waste during production. The Small Molecules (TCM) Business Division carried out process optimization for several products, including anti-inflammatory and choleretic dripping pills, improving raw material conversion rates and reducing material consumption per unit of product.

Cascaded energy utilization: The Company has built an energy recycling system to recover and reuse waste heat and surplus energy. In the Biologics Business Division, air conditioner condensate water at around 10°C in summer is recovered to cooling towers, lowering the outlet temperature of cooling water and reducing chiller energy consumption. In winter, steam condensate at around 90°C is recovered to preheat fresh air for air handling units, reducing annual steam consumption by approximately 200 tons. In the Small Molecules (TCM) Business Division, industrial steam condensate is recovered to boiler water tanks, with an annual recycling volume of 2,100 tons. In addition, secondary reverse osmosis concentrate is used for landscaping irrigation, saving 200 tons of tap water annually. In the Synthetic Biologics Business Division, process waste heat from production is recovered for uses such as material preheating, improving overall energy efficiency.

(III) Deepening green operations

1. Addressing climate change

Yifan Pharmaceutical actively responds to the national “dual carbon” strategy by integrating climate action into its overall development. Through multiple measures such as optimizing the energy mix, decarbonizing production processes, and promoting coordinated emissions reduction across the supply chain, the Company continuously reduces carbon intensity and fosters synergistic development between business operations and the environment.

The Company has established a carbon management system covering the entire industrial chain, set clear phased carbon reduction targets, and incorporated carbon emission control into departmental performance assessments. Regular carbon inventories are conducted to systematically collect Scope 1 (direct carbon emissions) and Scope 2 (indirect carbon emissions) data. In 2025, the Company completed a company-wide carbon inventory, forming a detailed record of carbon emissions to provide data support for targeted reduction strategies. Besides, the Company actively participates in industry carbon management exchanges, adopts best practices to optimize carbon management processes, and has obtained third-party carbon footprint verification for some of its sites, continuously improving the standardization of its carbon management practices.

Low-carbon energy mix

The Company is gradually phasing out energy varieties with high consumption and high emissions while promoting the application of clean energy. It has replaced coal with natural gas, phased out fuel-powered forklifts in favor of electric ones, and reduced direct carbon emissions. Solar panels have been installed on rooftops to lower fossil energy consumption through renewable energy utilization. Waste heat from local power plants is also used as industrial steam, saving water and reducing carbon emissions.

Emissions reduction in production

The Company optimizes production processes to reduce energy consumption during production; minimizes energy losses caused by frequent equipment start-stop cycles, reducing energy consumption per unit of product and indirectly lowering carbon emissions; and achieves coordinated reduction in both energy consumption and carbon emissions through equipment retrofitting.

Coordinated emissions reduction across the supply chain

Carbon reduction requirements are extended to the supply chain to drive low-carbon transformation across the entire chain. The Company reduces the number of logistics transport trips while optimizing cold chain transportation to cut carbon emissions from dry ice production, transportation, and sublimation. It promotes the localized substitution of packaging materials, shortening supply chain distances and eliminating the high carbon emissions associated with international air freight. The Company also adopts bulk raw material packaging instead of small packaging to reduce carbon emissions from packaging production and waste disposal.

In 2025, total greenhouse gas emissions amounted to **109,782.35** tCO_2e, with direct greenhouse gas emissions (Scope 1) of **31,126.53** tCO_2e and indirect greenhouse gas emissions (Scope 2) of **78,655.82** tCO_2e.

2. Protecting the ecological environment

Yifan Pharmaceutical thoroughly implements the *Opinions on Further Strengthening Biodiversity Protection* issued by the General Office of the Communist Party of China Central Committee and the General Office of the State Council. Guided by the *Environmental Protection Law of the People’s Republic of China* and the *Biosafety Law of the People’s Republic of China*, the Company has set the protection and sustainable use of biodiversity, the maintenance of biosafety and ecological security, the promotion of ecological civilization, and the harmonious coexistence between humanity and nature as its core development objectives.

Evive Biotechnology (Beijing) has developed and issued the *Measures for the Management of Biodiversity Protection* (EHS066-V1) as a standardized operating procedure for biodiversity conservation, which defines objectives, scope of application, division of responsibilities, implementation procedures, key terms, and other core elements, providing a unified and standardized framework for biodiversity management across the Company. Furthermore, based on these measures and aligned with national biodiversity protection policies, the Company has established an institutional support system covering the entire process, including survey and assessment, project control, ecological restoration, and education and training.

3. Implementing green concepts

Yifan Pharmaceutical has fully adopted green office practices, reducing energy consumption through measures targeting electricity, paper, and supplies. The Company has replaced lighting with LED energy-saving lamps, optimized air conditioning operating parameters with temperature standards of no lower than 26°C in summer and no higher than 20°C in winter, and implemented policies such as “lights off when leaving” and “power off after work”. In 2025, electricity consumption in office areas decreased significantly. The Company promotes digital office operations, with internal approvals, document transfers, and meeting communications all conducted through online systems. The use of recycled office supplies is encouraged, environmentally friendly office consumables are prioritized, and the use of disposable items (disposable pens and paper cups) is reduced.

The Company has integrated green office concepts into its corporate culture. Through internal training, bulletin boards, and corporate social media accounts, it regularly promotes environmental knowledge and green office techniques. A series of activities, including “Green Office Initiatives” and “Environmental Volunteering”, have been organized to encourage employee participation in practices such as office waste sorting and plant maintenance, creating a positive atmosphere where “everyone cares about the environment and integrates green practices into daily tasks”. Additionally, green office practices have been incorporated into employee conduct guidelines, guiding employees to develop good habits such as saving electricity, conserving water, and sorting waste, thereby translating green office concepts into voluntary actions.

Yifan Pharmaceutical, under the core principle of in-situ conservation as outlined in its *Measures for the Management of Biodiversity Protection*, organized to plant loquat and kumquat saplings. These activities enriched plant species diversity around the Company’s manufacturing sites, improved regional ecological micro-environments, and fulfilled the ecological restoration requirements of biodiversity protection. They also laid a solid practical foundation for future ecological restoration efforts at the sites and for achieving the goal of no net loss of biodiversity.

Yifan Pharmaceutical’s Tree Planting Practice

06

OPERATIONS TO CONSOLIDATE THE FOUNDATION FOR DEVELOPMENT

16 PEACE, JUSTICE AND STRONG INSTITUTIONS

Contributing to Sustainable Development Goals (SDGs)

Governance

In strict accordance with applicable laws and regulations and the *Articles of Association*, Yifan Pharmaceutical has established a governance framework with clearly defined powers and responsibilities and effective checks and balances, forming a complete closed-loop of "decision-making – execution – oversight". The Shareholders' Meeting, as the highest authority, exercises decision-making power over major matters, including electing directors, deliberating on profit distribution, increasing or decreasing registered capital, mergers, divisions, and other such issues.. The Board of Directors, as the executive body of the Shareholders' Meeting, is responsible for implementing resolutions, formulating operating plans, and appointing senior management. The management, entrusted by the Board of Directors, coordinates daily operations and core business activities to ensure decisions are implemented. The Audit Committee exercises the powers and functions of the Board of Supervisors as stipulated in the *Company Law*, overseeing the performance of duties at all levels. Additionally, it is responsible for reviewing the Company's financial information and its disclosure, supervising and evaluating internal and external audit work, internal controls, etc.. Additionally, the Company has further improved its structure through supporting mechanisms such as subsidiary control and related-party transaction regulations, ensuring coordinated and efficient operation across all levels.

Strategy

With the development goals of "innovation and internationalization", the Company pursues a strategy of refined governance to enhance governance effectiveness. This includes optimizing the division of powers and responsibilities in corporate governance, strengthening the closed-loop of decision-making, execution, and oversight to improve decision-making efficiency, and improving the internal control and audit systems to standardize full business processes and subsidiary management, thereby consolidating the foundation for compliance-based governance. The Company also implements a specialized talent governance strategy that optimizes incentive and restraint mechanisms, focusing on the retention and development of core talent to support key business growth. Furthermore, a collaborative governance strategy aligns the governance system closely with core business operations, integrating resources to support the implementation of the Company's overall strategic goals.

Risks and opportunities

Category	Specific content	Countermeasure
Compliance operation risk	Given the Company's numerous subsidiaries and diverse business operations, inadequate execution of internal control may lead to compliance risks and undermine the overall operational standardization.	Strengthen audit supervision, conduct regular internal control self-assessments, clarify subsidiary management authority and responsibilities, and ensure compliance across all business processes.
International governance risk	Significant differences in overseas market regulations and operating environments, coupled with difficulties in coordinating governance between domestic and overseas entities, may lead to operational and regulatory risks.	Establish governance mechanisms adapted to overseas markets, enhance coordination between domestic and overseas management teams, and precisely align with overseas regulatory requirements.
International development opportunity	A robust compliance governance system can meet overseas regulatory requirements, support innovative drugs in breaking into international markets, and increase global market share.	Continuously improve the compliance system, accurately adapt to regulatory standards in different overseas countries, accelerate the global expansion of innovative drugs, and broaden overseas presence.
Resource integration opportunity	An efficient governance structure can facilitate the integration of domestic and overseas resources, helping the Company seize industry policy benefits and optimize business layout.	Deepen governance-business collaboration, optimize resource allocation, focus on core businesses, proactively align with industry policies, and seize market opportunities.

Board meetings held: **6**

General meetings held: **3**

Policies revised: **17**

Cases of corruption or commercial bribery: **0**

(I) Strengthening corporate governance

1.Improving the governance structure



Organization Chart

The Shareholders' Meeting, as the highest authority of Yifan Pharmaceutical, makes decisions according to the law on the Company's major matters, including electing directors, deliberating on profit distribution, increasing or decreasing registered capital, mergers, divisions, and other such issues, and reviews and approves the Board of Directors' report, the Company's annual report, equity incentive plans, and other matters. The Company ensures that all shareholders, particularly minority shareholders, fully enjoy their legal rights as stipulated by laws, administrative regulations, and the *Articles of Association*. Pursuant to the provisions and requirements of the *Articles of Association* and the *Rules of Procedure for the Shareholders' Meeting*, it standardizes the convening, holding, and deliberation processes of general meetings, treats all shareholders equally, and facilitates shareholder participation by providing both on-site and online voting methods, ensuring that all shareholders, especially minority shareholders, can fully exercise their rights.

The Board of Directors, as the decision-making body of Yifan Pharmaceutical, reports to the Shareholders' Meeting. In strict accordance with the *Company Law*, the *Securities Law*, and the *Articles of Association*, the Company completed the election of a new Board of Directors and the appointment of senior management in September 2025. The Board of Directors and senior management are highly aligned with the Company's development path of "innovation, global expansion, and core business stabilization", thus facilitating the Company's long-term sustainable development. As of the end of 2025, the Board of Directors consisted of six directors, including two independent directors.

In 2025, six board meetings and three general meetings were held. In response to the latest laws and regulations, the Company revised 17 policies and formulated 2 new policies.

2. Strengthening investor communication

In accordance with the *Company Law*, the *Securities Law*, the *Guidelines for Investor Relations Management of Listed Companies*, and other applicable laws and regulations, the Company actively promotes investor relations management. It strengthens communication with investors through the interactive exchange platform, email, telephone, social media accounts, website, and on-site meetings. To protect the interests of small and medium-sized investors, the Company avoids selective disclosure to ensure that all shareholders have fair and equal access to company information.

Yifan Pharmaceutical, in strict accordance with the *Articles of Association*, the *Corporate Governance Guidelines for Listed Companies*, the *Management Measures for the Disclosure of Information of Listed Companies*, and other relevant provisions, has established and improved a comprehensive information disclosure system to ensure truthful, accurate, complete, and timely disclosure of information. The disclosure process is supervised and reviewed to promptly identify and correct any issues. The Company strictly complies with the fair disclosure principle for voluntary information disclosure, maintains the completeness, continuity and consistency of disclosed information, while ensuring no conflict with legally required disclosures, no selective disclosure, and no misleading of investors.

In 2025, the Company was awarded the “Golden Bull Award for Excellent Information Disclosure” by China Securities Journal. The Office of the Board Secretary actively performs its duties: It answered 418 investor questions through the interactive exchange platform, held two earnings presentations, and published 39 news releases. In addition, the Company proactively compiled shareholder opinions and submitted them to the management in the form of a monthly “Investor Voice Report”. Reasonable suggestions were reviewed and implemented to support operational management. The Company also completed 36 shareholder analyses, prepared 12 summaries of investor feedback.

3. Strengthening Party leadership

Party leadership serves as the fundamental guarantee for Yifan Pharmaceutical’s high-quality development. The Company upholds the Party’s overall leadership in corporate development by embedding Party building into the entire process of corporate governance, business development, and cultural cultivation. Guided by the Party’s leadership, the Company consolidates development synergy and addresses development challenges through tangible Party-building outcomes, transforming the Party’s strengths into competitive and developmental advantages. This approach aligns Party building with corporate growth, fostering mutual reinforcement and fulfilling the political responsibilities and social commitments of a pharmaceutical enterprise.

The Company places a strong emphasis on passing on revolutionary traditions and has designed immersive learning programs. Party members visited to revolutionary sites in Changsha and Nanchang, where they engaged in on-site learning, renewed their oath of allegiance to the Party, and held thematic seminars. Through these immersive and experiential activities, Party members deepened their ideological commitment, strengthened their sense of national responsibility and historical mission, and translated the revolutionary tradition of “firm conviction and hard work” into concrete actions—demonstrating dedication and resilience in their daily roles. Additionally, during key commemorative events, the Company organized thematic educational activities for Party members and active applicants, including site visits, expert-led sessions, and group discussions. These initiatives deepened participants’ understanding of the Party’s history and the nation’s past, reinforcing their commitment to the Party’s original aspirations and mission. Through these efforts, Party members strengthened the “Four Consciousnesses” and the “Four Confidences.” In addition, the Company persists in regular theoretical study without slackening, strictly implements the “First Agenda” system, and conducts ongoing political theory study through various forms such as central group study sessions, thematic Party lectures, and online learning platforms, so as to continuously enhance the political quality of Party members, systematically improve their political judgment, understanding, and execution, thereby laying a solid ideological foundation for the Company’s high-quality development.

Yifan Pharmaceutical’s Party Building Activities

(II) Strengthening risk management

1. Risk prevention and control mechanism

Yifan Pharmaceutical has established a systematic, multi-tiered risk management system covering its entire business process. With core control objectives including legal compliance, asset security, information authenticity, operational efficiency, and strategic execution, and supported by the tiered governance structure of the Shareholders’ Meeting, the Board of Directors, and the management, the Company has built an integrated risk control framework featuring clearly defined powers and responsibilities, mutual checks and balances, and collaborative oversight. A comprehensive system of policies and dedicated functional roles provides solid support for the implementation of risk management.

Leveraging the pharmaceutical industry profile and its unique operating characteristics (namely the dual-track development of “APIs + innovative drugs” and the globalized footprint), the Company comprehensively identifies potential risk factors across internal operations, external markets and policies, and business-specific dimensions. It has established a risk assessment mechanism that combines qualitative and quantitative approaches, utilizing historical data, industry case studies, and business development trends to scientifically evaluate the likelihood and potential impact of various risks. Following a risk-oriented principle, the Company conducts targeted reviews and prioritization, focusing precise control on high-risk areas such as fund management, R&D management, and quality control. For risks of different priorities and types, the Company deploys differentiated countermeasures including avoidance, reduction, transfer, mitigation, and continuous monitoring, specifies clear accountability and execution procedures for each risk, strictly controls the probability of high-priority risks, establishes early warning mechanisms for medium-priority risks, and dynamically tracks low-priority risks, effectively mitigating core risks and ensuring stable support for business development. Besides, the Company fully acknowledges the inherent limitations of internal controls and will continue to dynamically optimize its risk management system in response to industry conditions and business developments, steadily enhancing its risk identification, assessment, and response capabilities.

Control objectives

Based on the Basic Internal Control System, it aims to provide reasonable assurance regarding the lawful and compliant operation and management of the Company, the safety of its assets, the authenticity and completeness of financial reports and related information, enhance operational efficiency and effectiveness, and facilitate the Company in achieving its development strategies.

Risk analysis

Collect initial information for risk management:
Assess identified risks, including the likelihood and the severity of impact of each risk. Methods may include questionnaires, group discussions, expert consultations, scenario analysis, policy analysis, benchmarking, management interviews, and expert research.

Risk identification

Identify internal and external risk factors that may cause losses to the Company, including but not limited to financial risks, operational risks, compliance risks, etc. These risk factors may originate from the Company's management, operations, financial activities, and the external environment.

Response strategies

Justification for selecting the response plan and expected benefits;
Responsible persons for plan approval and execution;
Actions to be taken;
Resource requirements and emergency response plans;
Performance measures and constraints;
Reporting and monitoring.

2. Strengthening internal control systems

To enhance and standardize corporate internal control, continuously improve business management and risk prevention capabilities, and promote sustainable development, Yifan Pharmaceutical consistently adheres to core objectives of ensuring legal and compliant operations, asset security and integrity, and the accuracy and reliability of financial reports and related information. By continuously refining its internal management systems and operating rules, the Company has built a systematic, standardized, and normal internal control management framework, which is strictly implemented to provide solid support for stable operations and strategic execution. In August 2025, in response to regulatory requirements and actual management needs, the Company revised and improved core policies such as the *Internal Audit System* and the *Basic Internal Control System*, further enhancing the scientific rigor and applicability of its internal control system.

The establishment and improvement of the Company's internal control system not only respond to relevant regulatory requirements of the China Securities Regulatory Commission and stock exchanges and to the objective needs of adapting to the capital market governance system, but also serve as an internal necessity for strengthening governance capabilities, preventing operational risks, and achieving high-quality development. Focusing on key areas of internal control, the Company has developed and improved a series of policy documents, including the *Basic Internal Control System*, the *Financial Internal Control System*, and the *Internal Audit Management System for Human Resources*, forming a multi-layered internal control system with the basic policy as the guideline, specialized policies as support, and oversight mechanisms as safeguards. And, the Company conducts regular internal audits and special inspections on key areas such as procurement, project management, and production management, to embed internal control requirements into all business processes.

In terms of operational mechanisms, the Company has established a closed-loop management model covering risk identification, process control, supervision and rectification, and continuous improvement under the integrated internal control philosophy of "prevention before events, control during events, and handling after events". Through pre-event actions including policy improvement, authority clarification, risk assessment; in-event actions including process control strengthening, key point reviews, checks and balances, and dynamic monitoring; and post-event actions including internal audits, performance evaluations, and corrective accountability, the Company achieves comprehensive identification, effective control, and timely resolution of risks.

Through ongoing development and implementation, the Company's internal control system has significantly contributed to risk prevention and operational improvement. It effectively ensures operational compliance, asset security, and information integrity, solidifying the foundation of lawful operations. On the other hand, it significantly optimizes business processes, improves operational efficiency and management effectiveness, and enhances the Company's overall risk response capability. A well-structured and efficient internal control system not only improves the Company's governance level and capital market credibility but also provides solid institutional and managerial support for the company's sustained growth and strategic goal attainment.

3. Tax risk management

The Company integrates tax compliance and risk management into its overall governance framework, committed to building a transparent, efficient, and sustainable tax management system that supports business development and innovation while complying with global tax laws and regulations. To cope with the complex tax environment, the Company has established a normalized system for tax risk identification and response. During the reporting period, the Company led targeted reviews of tax base management and the utilization of preferential tax policies at key subsidiaries, systematically identifying multiple potential risk points, and a long-term risk list and response mechanisms were established to improve compliance with the application of major tax incentives. Through proactive, systematic screening, the Company successfully identified risks and implemented corrective measures, effectively controlling its overall tax risk exposure, proactively highlighting potential compliance issues in operations, and preventing tax-related risks at the source.

Through digital tools and ongoing knowledge sharing, the Company continuously enhances tax operational standardization and efficiency within the Company. During the reporting period, by integrating internal and external professional resources, the Company organized multiple tax-related operational and policy interpretation training sessions, including practical guidance on annual tax filing and final settlement, improving company-wide tax practices and efficiency in light of current policy developments. The Company efficiently completed full-year tax filing reviews and annual final settlements, and compiled internal case studies to facilitate knowledge sharing, ensuring the accurate and efficient operation of foundational tax work. As a result, the Company has maintained an excellent tax compliance record for many consecutive years.

(III) Upholding compliance standards

1.Conducting business with integrity

The Company highly values integrity, compliance, and anti-fraud risk prevention, advancing a long-term mechanism of “no dare for corruption, no opportunity for corruption, and no desire for corruption” to continuously reinforce the line of compliant operations and ethical conduct. To ensure accessible reporting channels, the Company has established special policies such as the *Whistleblowing Supervision System* and the *Anti-commercial Bribery Compliance Management System*, and set up diversified reporting channels including a complaint email, official social media accounts, telephone hotline, and questionnaires. Dedicated personnel review these channels daily, handle reports promptly, and conduct end-to-end tracking and investigation of each reported matter. Additionally, routine operational audits focus on identifying fraudulent behaviors and risk indicators. Any confirmed violations are strictly addressed in accordance with company policies.

The Company systematically advances a long-term mechanism of “no dare for corruption, no opportunity for corruption, and no desire for corruption” to comprehensively build a robust defense line for integrity, compliance, and risk prevention. In terms of “no dare for corruption”, the Company continuously conducts regular integrity education and compliance training. On December 18, 2025, an online integrity and anti-corruption training session was held for the Marketing Department of the Direct Operation Center, with analyzing typical internal audit findings and presenting anti-fraud case studies to guide employees to shift from passive rule-following to proactive compliance, thus to prevent fraudulent intentions at the source and safeguard the Company’s assets and operational stability. In terms of “no opportunity for corruption”, the Company has established a robust preventive system, strictly implementing the *Ten Prohibitions*, the *Whistleblowing Supervision System*, and the *Anti-commercial Bribery Compliance Management System*, which clearly define the red lines for various violations and misconduct, continuously address institutional gaps, and promote specific, targeted, and routine supervision. In terms of “no desire for corruption”, the Company strengthens deterrence and binding constraints through strict enforcement of the *Accountability and Penalty System for Audit and Supervision Findings*. Complaint reporting is managed through a standardized, end-to-end process, including initial review, investigation, resolution, and exoneration—all completed within required timeframes. A transparent, rule-based, and rigorous supervision and accountability mechanism is implemented to maintain order in its operations and management, foster a culture of integrity and ethics, and provide strong disciplinary assurance for compliant operations and high-quality development.

In 2025, Yifan Pharmaceutical recorded no cases of corruption or commercial bribery.

2. Related-party transaction management

To ensure that related-party transactions are conducted legally, compliantly, fairly, and impartially and to effectively safeguard the legitimate rights and interests of Yifan Pharmaceutical and its non-related shareholders, the Company has formulated the *Related-Party Transaction Decision-Making System* to comprehensively govern matters related to the related-party transactions in accordance with the *Company Law*, the *Securities Law*, the *Measures for the Administration of Independent Directors of Listed Companies*, the *Stock Listing Rules of the Shenzhen Stock Exchange*, the *Accounting Standard for Business Enterprises No. 36 – Disclosure of Related Parties, the Self-Regulatory Guidelines No. 7 for Companies Listed on the Shenzhen Stock Exchange – Transactions and Related-Party Transactions*, and other applicable laws, regulations, and normative documents, and based on its actual operating conditions. It clearly defines the criteria for identifying related relationships and related parties, and explicitly sets out the prerequisites and scope of related-party transactions, laying the foundation for the proper conduct of such transactions. Besides, the Company has established a dynamic management mechanism for maintaining a list of related parties, ensuring the truthfulness, accuracy, and completeness of related-party identification, thereby mitigating risks associated with related-party transactions at the source. This ensures fair and impartial decision-making processes, effectively prevents related-party transaction risks, and protects the legitimate rights and interests of the Company and all its shareholders.

3. Ensuring information security

To enhance its core security protection capabilities, Yifan Pharmaceutical places a particular emphasis on advancing full-cycle security reinforcement for data and endpoints and building proactive monitoring and early warning capabilities for infrastructure, thereby strengthening the foundation of information security. For data and endpoint security reinforcement, the Company has upgraded its encryption software, significantly enhancing defense capabilities against advanced threats such as ransomware and zero-day attacks, and systematically reducing the risk of endpoint data leakage. Endpoint security management strategies have been optimized, and an organizational structure synchronization mechanism has been improved to enable automated operations, effectively boosting management efficiency. Besides, upload-decryption and download-encryption policies have been deployed for the WPS cloud drive, further optimizing the online collaboration experience for all employees while ensuring core data security. Network access control has been strengthened through the full implementation of access authentication for terminals within the park. Mandatory identity verification and security compliance checks are performed on all devices attempting to connect to the network, preventing unauthorized or non-compliant devices from accessing the network at the source and effectively mitigating the risk of lateral attacks within the internal network. Regarding infrastructure monitoring and early warning, the Company has deployed and enhanced an integrated server performance and security monitoring system, enabling real-time visual monitoring and intelligent early warning of core infrastructure’s operational status, abnormal behavior, and potential security threats. This transforms the security operations model from “passive response” to “active detection and proactive remediation”, improving the proactivity and effectiveness of security management and control.

To further enhance its information security emergency response capabilities, Yifan Pharmaceutical has conducted practical drills to verify and strengthen the effectiveness of two emergency plans, establishing a closed-loop management system of “drill – review – improvement”. The Company completed off-site backup and recovery drills for core business data, establishing a data disaster recovery mechanism aligned with business continuity requirements. This ensures that critical data can be rapidly restored under extreme circumstances, safeguarding the resilience of the Company’s business operations. On the other hand, the Company once again organized a company-wide simulated phishing email drill and targeted training. Using highly realistic attack scenario simulations and focused guidance, these exercises further enhance employees’ ability to identify and respond to high-frequency social engineering attacks such as phishing emails, and help the Company continue to refine its emergency response procedures, thus steadily improving its overall emergency response capabilities in information security.

Future Outlook

As a new era begins, the path ahead is promising. Yifan Pharmaceutical remains committed to its medium- to long-term development strategies of "innovation and internationalization", with pharmaceutical preparations and synthetic biologics as its primary directions. While maintaining its existing business, especially high-quality operations, the Company will continuously innovate and transform.

The year 2026 marks the first year of the Company's new three-year plan. Adhering to its long-term development strategy and guided by the objectives of this three-year plan, the Company will adopt "innovation, revenue generation, and benchmarking" as its annual theme, advancing globalization across three dimensions—R&D, supply, and commercial—to drive high-quality and sustainable development.

To achieve this goal, the Company will focus on three key dimensions (innovation, supply chain, and commercial operations) to achieve coordinated breakthroughs. In terms of innovation, the Company will adopt a tiered approach to global markets, establish an R&D system relying on diverse innovation pathways, advance the progress of pipeline products, and build a differentiated and sustainable innovation landscape. Regarding the supply chain, the Company will adhere to international and domestic standards, advance new production capacities, integrate supply chain resources, optimize costs, and extend value through CMO and CDMO capabilities, forging sustainable competitiveness for "Yifan Manufacturing". In terms of commercial operations, the Company will implement differentiated layouts, leverage international platforms to deepen its presence both domestically and abroad, establish a virtuous cycle of "in-licensing and out-licensing", and solidify its position in the domestic market.

The Synthetic Biologics Business Division will deepen its advantages in core areas, accelerate the industrialization and commercialization of new products, and systematically advance the capabilities of the entire "R&D–manufacturing–commercialization" chain in the directions of "nutrition" and "personal care". While consolidating the market positions of existing products and ensuring basic performance, the division will actively drive new projects toward production, regulatory approval, and commercial launch, opening up entirely new growth trajectories.

We look forward to embarking on this new chapter of the journey together. We firmly believe that every act of perseverance and breakthrough is a profound response to the cause of human health. The future is already here. We will walk hand in hand with all our peers and supporters, steadily advancing on the path of protecting lives and co-creating a promising new chapter.

Appendices

(I) Key Performance Table

Economic performance

Category	Performance indicator	Unit	2025
Economy	Operating revenue	RMB100 million	51.33
	Net profit attributable to shareholders of the listed company	RMB100 million	4.02
	Total assets	RMB100 million	128.45
	Net assets	RMB100 million	88.35
	Total tax paid	RMB10,000	42,583.31
	Asset-liability ratio	%	32.18
	Social contribution value per share	RMB/share	1.43

*Statistical scope: Yifan Pharmaceutical Co., Ltd., consistent with the annual report

Environmental performance

Category	Performance indicator	Unit	2025
Environmental information disclosure	Total investment in environmental protection	RMB10,000	4,362.74
	Number of environmental monitoring actions	Time	450
	Number of participants in environmental protection training	Person	2,149
	Environmental protection training hours of employees	Hour	218
	Number of environmental emergency drills	Time	30
	Number of participants in environmental emergency drills	Person-time	860
	Number of green plants	Number	3
	Number of biodiversity protection policies	Number	1

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Category	Performance indicator	Unit	2025
Addressing climate change	Total greenhouse gas emissions	tCO_2e	109,782.35
	Direct greenhouse gas emissions (Scope 1)	tCO_2e	31,126.53
	Indirect greenhouse gas emissions (Scope 2)	tCO_2e	78,655.82
	Greenhouse gas emissions from combustion	tCO_2e	20,261.08
	Greenhouse gas emissions from processing	tCO_2e	8,704
	Greenhouse gas emissions from electricity	tCO_2e	49,031.60
	Greenhouse gas emissions from steam	tCO_2e	29,624.22
	Other greenhouse gas emissions generated	tCO_2e	2,161.45

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Environmental performance

Category	Performance indicator	Unit	2025
Pollutants and Waste	Number of pollution prevention and control policies	Number	111
	Total discharge of major pollutants	Ton	2,212.17
	Approved total discharge of major pollutants	Ton	2,474.42
	Excessive discharge of major pollutants	Ton	0
	Number of major administrative penalties due to pollutant discharge	Item	0
	Hazardous waste	Ton	2,872.34
	Hazardous waste intensity	Ton/ RMB10,000	4.24
	Non-hazardous waste	Ton	198.33
	Non-hazardous waste intensity	Ton/ RMB10,000	8.05
	Total general solid waste	Ton	2,650.91
	Waste pharmaceuticals (HW03)	Ton	97.72
	Laboratory waste liquid (HW49)	Ton	19.08
	Drug residue and sludge	Ton	6,102.98
	Office, domestic and other non-hazardous waste	Ton	42.09
	Total wastewater discharge	Ton	733,579.35
	Chemical oxygen demand (COD)	Ton	43.30
	Ammonia nitrogen	Ton	0.45
	Total waste gas emissions	Ton	280,453.87
	Nitrogen oxide (NO_x)	Ton	17.89
	Sulfur oxide (SO_x)	Ton	1.07
	Soot emission	Ton	1.12
	Other waste gas emissions	Ton	106,600.25
	Particulate matter	Ton	3.13
	Volatile organic compounds	Ton	183.89
	Carbon dioxide (CO_2)	Ton	16,780.99
	Number of environmental pollution accidents	Item	0
	Number of major administrative penalties due to environmental incidents	Item	0

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Category	Performance indicator	Unit	2025
Energy Management	Total direct energy consumption	Tce	7,323.19
	Diesel	Ton	32.09
	Natural gas	10,000 Nm^3	1,008.60
	Biomass fuel	Tce	1,119
	Direct energy consumption intensity	Tce/RMB10,000	57.32
	Total indirect energy consumption	10,000 kWh	11,918.36
	Total electricity consumption	10,000 kWh	9,758.17
	Purchased electricity	10,000 kWh	9,758.17
	Purchased steam	tCO_2e	175,919.14
	Indirect energy consumption intensity	10,000 kWh/RMB 10,000	46.64
	Total water consumption	Ton	543,715.59
	Fresh water consumption	Ton	543,715.59
	Water consumption intensity	Ton/RMB10,000	6,596.76
	Total water withdrawal	Ton	1,274,775.94
	Tap water withdrawal	Ton	771,042.94
	Surface water withdrawal	Ton	364,990
	Water withdrawal intensity	Ton/RMB10,000	7,900.84
	Total water discharge	Ton	731,060.35
	Discharge to surface fresh water (including rainwater, wetland water, river water and lake water)	Ton	26,895
	Discharge to a third-party site	Ton	704,165.35
	Recycled water volume	Ton	32,004,852
	Waste recycling volume	Ton	127.20
	Waste recycling rate	%	9.86
	Total investment in energy conservation and emission reduction	RMB10,000	559.86

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Social performance

Category	Performance indicator	Unit	2025
Scientific and technological innovation	Number of patent applications	Item	82
	Number of patents held (granted)	Item	294
	Number of newly granted patents for the year	Item	28
	Number of invention patents applied to the main business	Item	134
	Number of system certifications or qualifications held	Item	20
	Number of relevant R&D achievements	Item	35
	Number of R&D personnel	Person	836
	Proportion of R&D personnel to total employees	%	19.99
	Number of penalties for violation of technology ethics	Time	0

*Statistical scope: Yifan Pharmaceutical Co., Ltd., consistent with the annual report

Category	Performance indicator	Unit	2025
Supply chain management	Number of suppliers	Number	2,583
	Number of suppliers within the province	Number	1,439
	Number of suppliers outside the province	Number	1,144
	Procurement expenditure	RMB10,000	122,593.53
	Number of supplier assessments	Time	332
	Number of new suppliers	Number	15
	Number of suppliers that have signed an integrity commitment	Number	1,931

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Category	Performance indicator	Unit	2025
Products and services	Number of training sessions on product quality and servicea	Time	258
	Number of participants in training on product quality and service	Person	7,386
	Number of major safety and quality accidents related to products and services	Item	0
	Administrative penalties for safety and quality related to products and services	RMB10,000	0
	Number of product recalls due to safety and health reasons	Item	0

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, and the Synthetic Biologics Business Division

Category	Performance indicator	Unit	2025
Customers	Number of customer complaints	Item	467
	Customer complaint response rate	%	100
	Number of security accidents related to customer privacy leakage or theft	Item	0
	Amount involved in customer privacy leakage or theft	RMB10,000	0
	Number of violations or disciplinary incidents related to marketing and publicity	Item	0

* Statistical scope: The data includes the Biologics Business Division, the Small Molecules (TCM) Business Division, the Synthetic Biologics Business Division and the Global Business Division

Category	Performance indicator	Unit	2025
Employees	Labor contract signing rate	%	100
	Social insurance coverage rate	%	100
	Number of labor arbitrations or disputes	Time	6
	Number of annual paid leave days per capita	Day	9
	Total number of employees	Person	4,182
	Proportion of employees from ethnic minorities	%	2.2
	Number of disabled employees	Person	45
	Proportion of female executives (deputy general manager and above)	%	40
	Male employees	Person	2,398
	Female employees	Person	1,784
	Number of employees aged 30 and below	Person	1,010
	Number of employees aged 31-50	Person	2,548
	51 years old and above	Person	624
	Number of full-time employees	Person	4,182
	Number of part-time employees	Person	0
	Proportion of employees with Master's Degree or Higher	%	6.79
	Proportion of employees with Bachelor’s Degree	%	35.87
	Proportion of employees with Associate Degree or below	%	57.34
	Percentage of production staff	%	38.55
	Percentage of sales staff	%	23.91
	Percentage of technical staff	%	19.99
	Percentage of financial staff	%	3.90
	Percentage of administrative staff	%	2.30
	Percentage of managerial staff	%	11.35
	Number of senior management employees	Person	10
	Number of middle management employees	Person	464
	Number of general employees (including supervisors)	Person	3,753
	Number of new jobs created	Person	339
	Number of new male employees	Person	394
	Number of new female employees	Person	276

*Statistical scope: Yifan Pharmaceutical Co., Ltd., consistent with the annual report

Category	Performance indicator	Unit	2025
Employees	Number of new employees aged 30 and below	Person	363
	Number of new employees aged 31-50	Person	294
	Number of new employees aged 51 and above	Person	13
	Number of new disabled employees	Person	8
	Employee turnover rate	%	8.96
	Number of male employees who left	Person	319
	Number of female employees who left	Person	217
	Proportion of employees who return to work and retain their jobs after maternity/paternity leave	%	100
	Annual medical examination coverage of employees	%	100
	Number of occupational health and safety training sessions	Time	60
	Occupational health and safety training coverage rate	%	100
	Number of employees participating in occupational health and safety training	Person-time	2,687
	Number of safety emergency drills	Time	82
	Number of participants in safety emergency drills	Person-time	3,697
	Number of persons with occupational diseases	Person	0
	Number of work safety accidents	Number	0
	Number of work-related fatalities	Person	0
	Work-related fatality rate	%	0
	Number of work-related injuries	Person	9
	Number of working days lost due to work-related injuries	Day	299
	Working hours per capita	Hour	8
	Number of employee training programs	Time	192
	Employee training hours	Hour	6,450
	Number of employees trained	Person	3,000
	Amount invested in various types of training	RMB10,000	382.50
	Average training hours per male employee	Hour	7.2
	Average training hours per female employee	Hour	7.8
	Number of employees participating in professional skills training	Person	1,331
	Number of employees participating in vocational qualification training	Person	138
	Number of employees participating in academic qualification promotion	Person	13

Category	Performance indicator	Unit	2025
Social contribution	Total investment in public welfare activities	RMB10,000	601.76
	Number of volunteer activities organized	Time	31
	Number of participants in volunteer activities	Person-time	49
	Volunteer activity hours	Hour	186

*Statistical scope: Yifan Pharmaceutical Co., Ltd., consistent with the annual report

Governance performance

Category	Performance indicator	Unit	2025
Corporate governance	Number of personnel responsible for due diligence	Person	15
	Number of agencies responsible for due diligence	Number	5
	Number of board members	Person	6
	Number of board members aged 30and below	Person	0
	31-50 years old	Person	2
	Number of board members aged 51 and above	Person	4
	Number of female board members	Person	2
	Number of independent directors	Person	2
	Number of board meetings held	Time	6
	Number of proposals reviewed at board meetings	Item	45
	Number of general meetings held	Time	3
	Number of proposals reviewed at general meetings	Item	21
	Number of responses to stakeholder questions	Time	418
	Number of activities related to protecting medium and small investors	Time	3
Information disclosure	Number of information disclosure documents issued	Item	114
	Number of periodic reports	Item	72
	Number of interim reports	Item	42
Compliance governance	Number of commercial bribery-related violations	Item	0
	Number of corruption-related violations	Item	0
	Number of activities to prevent unfair competition	Time	10
	Number of incidents of unfair competition practices leading to litigation or major administrative penalties	Item	0
	Number of commercial bribery training sessions	Time	20
	Number of anti-corruption training sessions	Time	20
	Number of directors who received anti-commercial bribery and anti-corruption training	Person	4
	Proportion of directors who received anti-commercial bribery and anti-corruption training	%	67
	Number of management personnel who received anti-commercial bribery and anti-corruption training	Person	363
	Proportion of management personnel who received anti-commercial bribery and anti-corruption training	%	72
	Number of employees who received anti-commercial bribery and anti-corruption training	Person-time	2,669
	Proportion of employees who received anti-commercial bribery and anti-corruption training	%	63

*Statistical scope: Yifan Pharmaceutical Co., Ltd., consistent with the annual report

(II) Indicator Index Table

Report section		(GRI Standards)	*Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation)*
Report Description		2-2、2-3、207-4	Article 4、Article 6
Chairman's Address		2-11、2-22	/
About Us		2-1、2-6、201-1	Article 5
Special Topic I: Innovation Endures, Life Flourishes: R&D Breakthroughs and Health Commitments of Ryzneuta®		416-1、416-2	Article 5
Special Topic II: Global Support, Local Empowerment: Building an Open and Collaborative Pharmaceutical Innovation Ecosystem		2-6、416-1、416-2	Article 5
Sustainable Development Management	Sustainable development governance structure	2-9、2-12、2-13、2-14、2-22	Article 12、Article 51
	Stakeholder communication	2-16、207-3	Article 9、Article 53
	Material topic analysis	3-1、3-2、3-3、201-2	Article 5、Article 10、Article 14、Article 15
Innovation-driven Renewal of Products and Services	Innovating for a healthier future	2-23、2-27	Article 10、Article 11、Article 19、Article 41、Article 42、Article 43
	Advancing accessible healthcare	416-1、416-2	Article 5、Article 47
	Maintaining strict safety standards	2-27	Article 47
Collaboration for Mutual Success and Value Creation	Supply chain management	2-6、2-27、2-28、308-1、308-2	Article 10、Article 11、Article 44、Article 45
	Protecting customer rights	2-6、2-23、2-25、417-1、417-2、417-3、418-1	Article 19、Article 48
	Supporting public welfare initiatives	203-1、413-1、413-2、415-1	Article 38、Article 40
Safeguarding Employee Development with People-oriented Approaches	Safeguarding employee rights and interests	2-19、2-23、2-27、202-1、404-1、405-1、406-1、408-1、409-1	Article 10、Article 11、Article 19、Article 49、Article 50
	Safeguarding employee health	2-23、2-27、403-1、403-3、403-5、403-6、403-7、403-8	Article 19、Article 50
	Enhancing employee well-being	2-30、201-3、401-2、407-1	Article 50
Green Operations to Protect Our Common Home	Strengthening environmental management	2-23、2-27、306-1、306-2、306-3、306-4、306-5	Article 10、Article 11、Article 19、Article 29、Article 30、Article 31、Article 33
	Improving energy efficiency	301-2、301-3、302-1、302-4、303-1、303-2、303-5	Article 28、Article 34、Article 36、Article 37
	Deepening green operations	2-23、101-1、101-2、101-8、305-1、305-2、305-5	Article 19、Article 20、Article 21、Article 24、Article 27、Article 28、Article 32
Stable Operations to Consolidate the Foundation for Development	Strengthening corporate governance	2-9、2-10、2-23	Article 10、Article 11、Article 19、Article 51
	Strengthening risk management	2-12、2-24、201-4、207-1	Article 52
	Upholding compliance standards	2-15、2-23、2-24、2-27、205-2、205-3、206-1	Article 19、Article 54、Article 55、Article 56
Future Outlook		/	/
Key Performance Table		2-7、201-1、204-1、205-2、302-1、302-4、303-3、303-4、303-5、305-1、305-2、305-7、306-3、308-1、401-1、403-5、404-1、404-3、415-1	Article24、Article25
Indicator Index Table		/	/
Independent Assurance Report		2-5	/
Reader Feedback		2-29	/

(III) Independent Assurance Report

BDO 立信 立信会计师事务所(特殊普通合伙)
BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

关于亿帆医药股份有限公司
2025 年度可持续发展
报告的鉴证报告

信会师报字[2026]第 ZB10645 号

亿帆医药股份有限公司董事会：

我们接受委托，对亿帆医药股份有限公司（以下简称“亿帆医药”）《2025年度可持续发展报告》（以下简称“《可持续发展报告》”）中选定的2025年度关键数据（以下简称“2025年度关键数据”）执行了有限保证的鉴证业务。

关键数据

本报告就亿帆医药《可持续发展报告》中的下列 2025 年度关键数据实施了有限保证鉴证工作程序：

- 每股社会贡献值
- 境内耗水量
- 境内耗电量
- 温室气体排放总量
- 有害废弃物
- 研发投入总额
- 劳动合同签订率
- 公益捐赠支出
- 职业健康安全培训覆盖率
- 回复利益相关方问题
- 开展商业贿赂培训数量
- 接受反商业贿赂及反贪污培训的管理层人员总数

我们的鉴证工作仅限于上述2025年度关键数据，《可持续发展报告》中披露的以前年度关键数据和其他信息不在我们的工作范围内。

标准

亿帆医药编制《可持续发展报告》关键数据所采用的标准列示于《可持续发展报告》“报告说明”的“编制依据”（以下简称“编制依据”）中。

鉴证报告 第 1页

BDO 立信 立信会计师事务所(特殊普通合伙)
BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

管理层的责任

按照编制依据编制2025年度关键数据是亿帆医药管理层的责任。这种责任包括设计、执行和维护与编制企业环境、社会和公司治理（可持续发展）报告关键数据有关的内部控制，以使关键数据不存在由于舞弊或错误而导致的重大错报。

注册会计师的责任

我们的责任是在执行鉴证工作的基础上对 2025 年度关键数据发表结论。

我们根据《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证工作。该准则要求我们遵守职业道德规范，计划和实施工作，以形成鉴证结论。

有限保证鉴证业务所实施程序的性质和时间较合理保证鉴证业务有所不同，且范围较小。因此，有限保证鉴证业务的保证程度远低于合理保证鉴证业务。因此，我们不会就 2025 年度关键数据是否在所有重大方面按照编制依据编制发表合理保证意见。我们的鉴证工作包括评估 2025 年度关键数据是否存在由于舞弊或错误导致的重大错报风险，以及应对评估出的风险。选择的鉴证程序取决于我们的判断及对项目风险的评估。在我们的工作范围内，我们仅在亿帆医药及下属境内主要子公司层面对关键数据开展工作。我们不对除亿帆医药及下属境内主要子公司外的其他分支机构实施鉴证工作。我们执行的工作包括：

1) 与亿帆医药负责编制《可持续发展报告》的部门负责人及相关人员进行访谈；
2) 与参与提供 2025 年度关键数据基础信息的相关部门人员进行访谈；
3) 实施分析程序；
4) 了解和测试与 2025 年度关键数据相关的内部控制；
5) 采用抽样方法检查 2025 年度关键数据的支持性文件和记录；
6) 重新计算 2025 年度关键数据；

固有限制

我们提请使用者注意，针对非财务数据，尚无公认的评估和计量标准体系，因此存在不统一的计量方法，这将会影响不同公司之间数据的可比性。

鉴证报告 第 2页



BDO 立信 立信会计师事务所(特殊普通合伙)
BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

结论

基于已实施的程序及获取的证据，我们没有注意到任何事项使我们相信亿帆医药《可持续发展报告》中选定的2025年度关键数据未能在所有重大方面按照编制依据编制。

报告使用限制

本报告仅向亿帆医药董事会出具，用于披露《可持续发展报告》的目的使用，不适用于任何其他目的。我们不会就本报告的内容向任何其他方承担任何责任或义务。

立信会计师事务所（特殊普通合伙）

中国注册会计师：刘海山

中国注册会计师 刘海山 110001530009

中国注册会计师：晁喜文

中国注册会计师 晁喜文 330000140205

中国•上海　　2026年4月22日

鉴证报告 第3页

(IV) Reader Feedback

Thank you for reading the *2025 Sustainability Report of Yifan Pharmaceutical Co., Ltd*. To offer you and other stakeholders more valuable insights, improve oversight of our sustainability efforts, and boost our social responsibility performance, we welcome your valuable comments and suggestions on this report.

1. What is your overall assessment of Yifan Pharmaceutical's Sustainability Report?

□ Excellent □ Good □ Average □ Below Average □ Poor

2. How would you rate Yifan Pharmaceutical's performance in fulfilling environmental, social, and governance (ESG) responsibilities?

Environmental responsibility: □ Excellent □ Good □ Average □ Below Average □ Poor

Social responsibility:□ Excellent □ Good □ Average □ Below Average □ Poor

Corporate governance: □ Excellent □ Good □ Average □ Below Average □ Poor

3. Do you believe this report effectively reflects the influence of Yifan Pharmaceutical's social responsibility practices on sustainability?

□ Very effectively □ Quite effectively □ Moderately effectively □ Not very effectively □ Not at all effectively

4. How would you rate the clarity, accuracy, and completeness of the information, data, and indicators disclosed in this report?

Clarity: □ Excellent □ Good □ Average □ Below Average □ Poor

Accuracy: □ Excellent □ Good □ Average □ Below Average □ Poor

Completeness: □ Excellent □ Good □ Average □ Below Average □ Poor

5. Do you find the content organization and layout design of this report convenient for reading?

□ Yes □ Average □ No

6. Do you have any other comments or suggestions regarding Yifan Pharmaceutical's sustainability work and this report?